


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:08Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406409" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406409</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcid</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">36</journal-id><journal-id journal-id-type="pmc-domain">bmcid</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406409</article-id><article-id pub-id-type="pmcid-ver">PMC12406409.1</article-id><article-id pub-id-type="pmcaid">12406409</article-id><article-id pub-id-type="pmcaiid">12406409</article-id><article-id pub-id-type="pmid">40898108</article-id><article-id pub-id-type="doi">10.1186/s12879-025-11527-9</article-id><article-id pub-id-type="publisher-id">11527</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Associations of lactate-to-hematocrit ratio with short- and long-term prognoses in critically ill patients with cirrhosis and sepsis: a retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jianjun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="S">Sirui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="Z">Zhaohui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yancheng</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="R">Ruizi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qin</surname><given-names initials="C">Chuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Gong</surname><given-names initials="J">Jianping</given-names></name><address><email>gongjianping11@126.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zeng</surname><given-names initials="X">Xintao</given-names></name><address><email>zengxintao@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="D">Decai</given-names></name><address><email>decaiwang_2020@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00s528j33</institution-id><institution-id institution-id-type="GRID">grid.490255.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 7594 4364</institution-id><institution>Department of Hepatobiliary Surgery, School of Medicine, </institution><institution>Mianyang Central Hospital, University of Electronic Science and Technology of China, </institution></institution-wrap>Mianyang, 621000 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00s528j33</institution-id><institution-id institution-id-type="GRID">grid.490255.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 7594 4364</institution-id><institution>NHC Key Laboratory of Nuclear Technology Medical Transformation, School of Medicine, </institution><institution>Mianyang Central Hospital, University of Electronic Science and Technology of China, </institution></institution-wrap>Mianyang, 621000 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00r67fz39</institution-id><institution-id institution-id-type="GRID">grid.412461.4</institution-id><institution>The Second Affiliated Hospital of Chongqing Medical University, </institution></institution-wrap>Chongqing, 400010 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017z00e58</institution-id><institution-id institution-id-type="GRID">grid.203458.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 8653 0555</institution-id><institution>College of Traditional Chinese Medicine, </institution><institution>Chongqing Medical University, </institution></institution-wrap>Chongqing, 400016 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00s528j33</institution-id><institution-id institution-id-type="GRID">grid.490255.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 7594 4364</institution-id><institution>Department of Urology, School of Medicine, </institution><institution>Mianyang Central Hospital, University of Electronic Science and Technology of China, </institution></institution-wrap>Mianyang, 621000 China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478176</issue-id><elocation-id>1095</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12879_2025_Article_11527.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The lactate-to-hematocrit ratio (LHR) is strongly associated with the prognosis of patients critically ill with various diseases. However, the relationship between LHR and the prognosis of critically ill patients with cirrhosis and sepsis has not been explored. Therefore, this study examined the association between the LHR and short- and long-term prognoses in this special group of patients.</p></sec><sec><title>Methods</title><p id="Par2">Hospitalization data of patients with cirrhosis and sepsis in an intensive care unit between 2008 and 2022 were retrospectively analyzed. The LHR was calculated from arterial blood lactate and hematocrit levels obtained during the first measurement within 24&#160;h of admission. The threshold for optimal LHR was determined using standard statistical tools in R. The risks of death were compared between patients with LHR values above and below this threshold. Multivariate Cox proportional hazards regression models were used to examine the association between LHR and the short- and long-term mortality risks in this group of patients. The potential dose-response relationship between LHR and mortality were investigated. Additionally, the predictive ability, sensitivity, and specificity of LHR for the risk of all-cause mortality were evaluated. Finally, subgroup analyses were performed to assess the relationship between LHR and prognosis in different populations.</p></sec><sec><title>Results</title><p id="Par3">Among the 1881 patients included in this study, the threshold LHR was 0.12. Kaplan&#8211;Meier analysis showed that patients with higher LHR had significantly higher risks of intensive care unit (ICU); in-hospital; and 14-, 28-, and 90-day mortality (all log-rank <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). The multivariate Cox proportional hazards models suggested an independent association between high LHR and 14-, 28-, and 90-day all-cause mortalities. RCS analyses showed a nonlinear association between LHR and short- and long-term all-cause mortality in patients with cirrhosis and sepsis. ROC curve analyses showed that LHR had a better predictive ability for prognosis in patients with cirrhosis combined with sepsis than other indicators. Subgroup analysis showed no significant interaction between LHR and most of the subgroups.</p></sec><sec><title>Conclusion</title><p id="Par4">High LHR values were strongly associated with poor short- and long-term prognoses in critically ill patients with cirrhosis and sepsis.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12879-025-11527-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cirrhosis</kwd><kwd>Sepsis</kwd><kwd>Lactate-to-hematocrit ratio</kwd><kwd>All-cause mortality, intensive care unit</kwd></kwd-group><funding-group><award-group><funding-source><institution>NHC Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital)</institution></funding-source><award-id>Grant no.2023HYX032</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Jianjun</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Scientifc Research Project of Mianyang Health Commission</institution></funding-source><award-id>Grant no. 201926</award-id><principal-award-recipient><name name-style="western"><surname>Hu</surname><given-names>Zhaohui</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Clinical Special Project of Mianyang Central Hospital</institution></funding-source><award-id>Grant no.2024LC007</award-id><principal-award-recipient><name name-style="western"><surname>Zeng</surname><given-names>Xintao</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China (NSFC)</institution></funding-source><award-id>Grant no.82400758</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Decai</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Health Commission of Sichuan Province Medical Science and Technology Program</institution></funding-source><award-id>Grant no.24QNMP028</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Decai</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Medical Research Youth Innovation Project of Sichuan Province, China</institution></funding-source><award-id>Grant no.Q23046</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Decai</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par21">Cirrhosis, the end stage of chronic liver disease, affects over 2.2&#160;million adults in the United States and carries a mortality rate of 21.9 per 100,000 population [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. Due to immune dysfunction, microcirculatory alterations, and intestinal dysbiosis, patients with cirrhosis are particularly susceptible to infections and have a significantly increased risk of developing sepsis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Once sepsis occurs, prognosis deteriorates markedly, highlighting the need for effective prognostic tools to facilitate early risk assessment and guide management.</p><p id="Par22">Lactate (LAC), a well-established marker of tissue hypoperfusion and cellular hypoxia, is commonly used in sepsis evaluation and has been consistently linked to increased mortality in critically ill patients [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. However, its specificity is limited in cirrhotic patients due to impaired hepatic clearance and drug effects [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Hematocrit (HCT), a routine measure of red blood cell volume and oxygen-carrying capacity, is also affected by inflammation, fluid shifts, and bleeding during sepsis, and low levels have been associated with poor outcomes [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Both LAC and HCT, however, are subject to confounding when interpreted independently.</p><p id="Par23">Recent studies have emphasized the value of combined biomarkers, such as the lactate-to-albumin ratio (LAR), blood urea nitrogen-to-albumin ratio (BUN/ALB), and neutrophil-to-lymphocyte ratio (NLR), for improving prognostic precision in critical illness [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>]. In this context, Demir et al. [<xref ref-type="bibr" rid="CR22">22</xref>] proposed the lactate-to-hematocrit ratio (LHR) as a novel index with high sensitivity and specificity for predicting mortality in patients with severe trauma.</p><p id="Par24">While promising, the role of LHR has not been examined in patients with cirrhosis complicated by sepsis. As both LAC and HCT are readily available, LHR may serve as a simple yet informative composite marker, reflecting both tissue hypoxia and oxygen delivery deficits&#8212;two key features in this population.</p><p id="Par25">Therefore, the present study aimed to investigate the association between LHR and short- and long-term all-cause mortality (14-, 28-, and 90-day) in critically ill patients with cirrhosis and sepsis, using data from the MIMIC-IV (v3.0) database. Our goal was to evaluate the prognostic utility of LHR and provide new insights into early risk stratification in this high-risk population.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and data source</title><p id="Par26">This was a retrospective observational study, and all analyses were conducted in a data-driven and hypothesis-generating manner.</p><p id="Par27">The clinical data of the participants were obtained from the MIMIC-IV (v 3.0) database, a publicly available resource created by the Computational Physiology Laboratory at MIT. This database encompasses medical records from patients admitted to the Beth Israel Deaconess Medical Center. To access MIMIC-IV (v3.0), our research team successfully completed the Collaborative Institutional Training Initiative (CITI) program, passed the relevant Conflict of Interest and Research Data or Specimen-Only examinations, and received formal authorization.</p></sec><sec id="Sec4"><title>Study population</title><p id="Par28">Data on patients diagnosed with cirrhosis and sepsis were retrieved based on codes from the International Classification of Diseases, 9th and 10th Revisions (ICD-9 and ICD-10) (Supplementary Material). In accordance with the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis 3.0), individuals were identified as having sepsis if they had a suspected infection&#8212;indicated by the administration of antibiotics and the ordering of microbiological culture tests&#8212;and a Sequential Organ Failure Assessment (SOFA) score of 2 or higher [<xref ref-type="bibr" rid="CR23">23</xref>]. To ensure the robustness of the results, we excluded patients who [<xref ref-type="bibr" rid="CR1">1</xref>] were &lt;&#8201;18 years of age at the time of their first admission (<italic toggle="yes">n</italic>&#8201;=&#8201;0) [<xref ref-type="bibr" rid="CR2">2</xref>], had an intensive care unit (ICU) stay of &lt;&#8201;24&#160;h (<italic toggle="yes">n</italic>&#8201;=&#8201;281), and [<xref ref-type="bibr" rid="CR3">3</xref>] lacked LAC and HCT information recorded within 24&#160;h following ICU admission (<italic toggle="yes">n</italic>&#8201;=&#8201;410). Only the first stay was analyzed among patients with multiple ICU admissions (<italic toggle="yes">n</italic>&#8201;=&#8201;880). Ultimately, this study included 1881 patients (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par29">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flowchart for patients with cirrhosis and combined sepsis from MIMIV-IV (v 3.0)</p></caption><graphic id="d33e481" position="float" orientation="portrait" xlink:href="12879_2025_11527_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec5"><title>Covariate extraction</title><p id="Par30">Covariate data were collected, including demographic characteristics, vital signs, comorbidities, cirrhosis etiology (determined based on ICD-9/10 diagnosis codes), laboratory results, clinical treatments, survival outcomes, and microbiological culture findings (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). For consistency, we extracted the first available measurement within the first 24&#160;h following ICU admission. The tools used for data extraction consisted of PostgresSQL software (version 13.7.2) and Navicate Premium software (version 16). Structured Query Language (SQL) was applied to retrieve the required data efficiently.</p><p id="Par31">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Covariates extracted in detail from MIMIC-IV (v 3.0)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Items</th><th align="left" colspan="1" rowspan="1">Composition</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Demographic variables</td><td align="left" colspan="1" rowspan="1">Age, Gender, Ethnicity</td></tr><tr><td align="left" colspan="1" rowspan="1">Comorbidities</td><td align="left" colspan="1" rowspan="1">Hypertension, Diabetes mellitus, Chronic obstructive pulmonary disease, Coronary heart disease, Myocardial infarction, Ascites, Hepatorenal syndrome, Malignancy, Heart failure, Atrial fibrillation, Hepatic encephalopathy, Esophagealvarices with hemorrhage, Hepatic failure, Septic shock</td></tr><tr><td align="left" colspan="1" rowspan="1">Vital signs</td><td align="left" colspan="1" rowspan="1">Heart rate, Systolic blood pressure, Diastolic blood pressure, Mean arterial pressure, Respiratory rate, SPO2, Temperature</td></tr><tr><td align="left" colspan="1" rowspan="1">Laboratory parameters</td><td align="left" colspan="1" rowspan="1">Neutrophil cells, Lymphocyte cells, Red blood cells, White blood cells, Erythrocyte distribution width, Platelet, Hemoglobin, Lymphocyte percentage, Hematocrit, Creatinine, Blood urea nitrogen, Albumin, Total bilirubin, Direct bilirubin, Aspartate aminotransferase, Alanine aminotransferase, Glucose, Triglyceride, Total cholesterol, High density lipoprotein cholesterol, Low density lipoprotein cholesterol, Prothrombin time, International normalized ratio, Potassium, Sodium, Calcium, Anion gap, Lactate, PH, FiO2, PCO2, PaO2</td></tr><tr><td align="left" colspan="1" rowspan="1">Clinical treatments</td><td align="left" colspan="1" rowspan="1">Urinary catheter, Vasopressin, Ventilation, Continuous Renal Replacement Therapy, Norepinephrine</td></tr><tr><td align="left" colspan="1" rowspan="1">Clinical outcomes</td><td align="left" colspan="1" rowspan="1">ICU mortality, Hospital mortality, 14-day all-cause mortality, 28-day all-cause mortality, 90-day all-cause mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">Scores</td><td align="left" colspan="1" rowspan="1">Sequential Organ Failure Assessment, Model for End-Stage Liver Disease score</td></tr><tr><td align="left" colspan="1" rowspan="1">Others</td><td align="left" colspan="1" rowspan="1">Causes of liver cirrhosis, Infections positions, Microculture and Antibacterial agents</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec6"><title>Management of abnormal and missing values</title><p id="Par32">To address outliers in continuous variables, we applied the Winsorization method using the STATA winsor2 command, with thresholds set at the 1&#8201;st and 99th percentiles. This approach constrains extreme values to reduce their undue influence on model estimates while preserving the sample size and data structure. Compared to deletion, Winsorization minimizes estimation bias and maintains the robustness of statistical inferences, particularly in large clinical datasets where measurement variability and input errors are common [<xref ref-type="bibr" rid="CR24">24</xref>]. Missing data were addressed using multiple imputation by chained equations, which preserves sample size and reduces selection bias under the assumption of missing at random. This approach accounts for uncertainty in imputed values and has been extensively applied in studies using the MIMIC database. To ensure data quality, variables with more than 15% missingness were excluded from the analysis.</p></sec><sec id="Sec7"><title>Groups and clinical outcomes</title><p id="Par33">The optimal cutoff value for the LHR (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) was determined after confirming that LHR was significantly associated with mortality outcomes when treated as a continuous variable, using the surv_cutpoint function from the &#8220;survminer&#8221; package in R (version 4.2.2), based on the primary outcome of 28-day all-cause mortality. This function implements the maximally selected rank statistics method, which identifies the threshold that maximizes the log-rank statistic, thereby optimally separating patients into groups with significantly different survival outcomes. Key parameters included minprop&#8201;=&#8201;0.1 (to ensure that each group comprised at least 10% of the cohort) and method = &#8220;logrank&#8221;.</p><p id="Par34">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The choice of the optimal cutoff point maximized the risk ratio and the relationship between LHR&#8201;&#8805;&#8201;0.12 and the distribution of LHR</p></caption><graphic id="d33e570" position="float" orientation="portrait" xlink:href="12879_2025_11527_Fig2_HTML.jpg"/></fig>
</p><p id="Par35">Patients were subsequently categorized into a low LHR group (LHR&#8201;&lt;&#8201;0.12, <italic toggle="yes">n</italic>&#8201;=&#8201;1252) and a high LHR group (LHR&#8201;&#8805;&#8201;0.12, <italic toggle="yes">n</italic>&#8201;=&#8201;629). The primary outcome was defined as 28-day all-cause mortality from the time of first ICU admission, based on the intime timestamp in the icustays table of the MIMIC-IV database. The secondary outcomes were 14-day and 90-day all-cause mortality, also calculated from the time of ICU admission.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par36">Continuous variables following a normal distribution were presented as mean&#8201;&#177;&#8201;standard deviation and analyzed using the t-test or analysis of variance (ANOVA) for group comparisons. For continuous variables that did not meet the normality assumption, data were expressed as medians with interquartile ranges and compared across groups using the Mann&#8211;Whitney U-test or the Kruskal&#8211;Wallis test. Categorical variables were reported as frequencies (percentages) and evaluated using chi-square tests or Fisher&#8217;s exact tests, as appropriate.</p><p id="Par37">In this study, to assess the primary association between LHR and prognosis before any grouping, Cox proportional hazards models were used to evaluate the association between the LHR and patient prognosis. Model 1 was unadjusted, Model 2 adjusted for age, sex, and ethnicity, and Model 3 further adjusted for clinical variables including SOFA score, serum creatinine level, white blood cell and platelet counts, hypertension, heart failure, respiratory failure, diabetes, vasopressin use, and continuous renal replacement therapy.</p><p id="Par38">Before model construction, the proportional hazards (PH) assumption was evaluated using Schoenfeld residuals via the cox.zph function in R. No violations of the PH assumption were detected (<italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05), and visual inspection of Schoenfeld residual plots confirmed the constancy of hazard ratios over time. To address potential multicollinearity, particularly due to overlap between the SOFA score and its components such as platelet count and respiratory failure, we calculated the variance inflation factor (VIF) for all covariates in Model 3. All VIF values were below 5, suggesting that collinearity did not significantly affect the model.</p><p id="Par39">Kaplan&#8211;Meier survival analyses were used to assess ICU, in-hospital, and 14-, 28-, and 90-day mortalities in patients according to LHR group, with the log-rank test used to compare differences between the two sets of curves. It should be noted that these survival analyses were conducted only after the continuous variable LHR showed a statistically significant association with mortality.</p><p id="Par40">To explore the dose-response relationship between LHR and 14-, 28-, and 90-day all-cause mortality, restricted cubic spline (RCS) models were employed. These analyses further supported the association between LHR and mortality without presupposing linearity.</p><p id="Par41">Receiver operating characteristic (ROC) analysis was conducted to evaluate the ability of LHR to predict the risk of all-cause mortality at various time points, with the area under the curve (AUC) calculated.</p><p id="Par42">Additionally, subgroup analyses were performed to examine the consistency of LHR&#8217;s prognostic value across different patient categories, including age, sex, hypertension, respiratory failure, and coronary heart disease.</p><p id="Par43">Statistical significance was set at a two-tailed <italic toggle="yes">P</italic>-value of less than 0.05. Data analysis was performed using R software (version 4.2.2), STATA (version 16.0), and IBM SPSS Statistics for Windows (version 22.0).</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Comparison of baseline characteristics between 28-day survivors and non-survivors</title><p id="Par44">To preliminarily explore the prognostic relevance of LHR, we first stratified patients based on their 28-day survival status. Among the 1,881 critically ill patients with cirrhosis and sepsis, 646 (34.34%) died within 28 days of ICU admission. Baseline characteristics of survivors and non-survivors are presented in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. Compared with survivors, non-survivors had significantly higher prevalence of ascites, hepatorenal syndrome, hepatic failure, and septic shock. Vital signs such as heart rate and respiratory rate were elevated, whereas systolic and diastolic blood pressure, mean arterial pressure, and body temperature were notably lower.</p><p id="Par45">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Baseline characteristics of patients with cirrhosis and sepsis stratified by 28-day survival status</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="left" colspan="1" rowspan="1">Overall (<italic toggle="yes">n</italic>&#8201;=&#8201;1881)</th><th align="left" colspan="1" rowspan="1">Survivor (<italic toggle="yes">n</italic>&#8201;=&#8201;1235)</th><th align="left" colspan="1" rowspan="1">Non-survivor (<italic toggle="yes">n</italic>&#8201;=&#8201;646)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">LHR</td><td align="left" colspan="1" rowspan="1">0.09 (0.06&#8211;0.15)</td><td align="left" colspan="1" rowspan="1">0.08 (0.05&#8211;0.13)</td><td align="left" colspan="1" rowspan="1">0.11 (0.07&#8211;0.19)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Demographics</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Age, years</td><td align="left" colspan="1" rowspan="1">58 (50&#8211;65)</td><td align="left" colspan="1" rowspan="1">57 (49&#8211;64)</td><td align="left" colspan="1" rowspan="1">59 (52&#8211;68)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Men, n (%)</td><td align="left" colspan="1" rowspan="1">1208 (64.22)</td><td align="left" colspan="1" rowspan="1">801 (64.86)</td><td align="left" colspan="1" rowspan="1">407 (63.00)</td><td align="left" colspan="1" rowspan="1">0.42</td></tr><tr><td align="left" colspan="5" rowspan="1">Ethnicity, n (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Asian population</td><td align="left" colspan="1" rowspan="1">46 (2.45)</td><td align="left" colspan="1" rowspan="1">31 (2.51)</td><td align="left" colspan="1" rowspan="1">15 (2.32)</td><td align="left" colspan="1" rowspan="1">0.003</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;White population</td><td align="left" colspan="1" rowspan="1">1183 (62.89)</td><td align="left" colspan="1" rowspan="1">799 (64.70)</td><td align="left" colspan="1" rowspan="1">384 (59.44)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Black population</td><td align="left" colspan="1" rowspan="1">138 (7.34)</td><td align="left" colspan="1" rowspan="1">100 (8.10)</td><td align="left" colspan="1" rowspan="1">38 (5.88)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Others</td><td align="left" colspan="1" rowspan="1">514 (27.33)</td><td align="left" colspan="1" rowspan="1">305 (24.70)</td><td align="left" colspan="1" rowspan="1">209 (32.35)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">&#8195;Causes of liver cirrhosis, n (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Alcohol</td><td align="left" colspan="1" rowspan="1">839 (44.60)</td><td align="left" colspan="1" rowspan="1">520 (42.11)</td><td align="left" colspan="1" rowspan="1">319 (49.38)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Viral</td><td align="left" colspan="1" rowspan="1">523 (27.80)</td><td align="left" colspan="1" rowspan="1">374 (30.28)</td><td align="left" colspan="1" rowspan="1">149 (23.07)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Biliary</td><td align="left" colspan="1" rowspan="1">38 (2.02)</td><td align="left" colspan="1" rowspan="1">33 (2.67)</td><td align="left" colspan="1" rowspan="1">5 (0.77)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Others</td><td align="left" colspan="1" rowspan="1">481 (25.57)</td><td align="left" colspan="1" rowspan="1">308 (24.94)</td><td align="left" colspan="1" rowspan="1">173 (26.78)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Comorbidities</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hypertension, n (%)</td><td align="left" colspan="1" rowspan="1">1243 (66.08)</td><td align="left" colspan="1" rowspan="1">851 (68.91)</td><td align="left" colspan="1" rowspan="1">392 (60.68)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diabetes mellitus, n (%)</td><td align="left" colspan="1" rowspan="1">580 (30.83)</td><td align="left" colspan="1" rowspan="1">406 (32.87)</td><td align="left" colspan="1" rowspan="1">174 (26.93)</td><td align="left" colspan="1" rowspan="1">0.008</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Chronic obstructive pulmonary disease, n (%)</td><td align="left" colspan="1" rowspan="1">134 (7.12)</td><td align="left" colspan="1" rowspan="1">75 (6.07)</td><td align="left" colspan="1" rowspan="1">59 (9.13)</td><td align="left" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Heart failure, n (%)</td><td align="left" colspan="1" rowspan="1">301 (16.00)</td><td align="left" colspan="1" rowspan="1">227 (18.38)</td><td align="left" colspan="1" rowspan="1">74 (11.46)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Myocardial infarction, n (%)</td><td align="left" colspan="1" rowspan="1">231 (12.28)</td><td align="left" colspan="1" rowspan="1">161 (13.04)</td><td align="left" colspan="1" rowspan="1">70 (10.84)</td><td align="left" colspan="1" rowspan="1">0.17</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ascites, n (%)</td><td align="left" colspan="1" rowspan="1">1006 (53.48)</td><td align="left" colspan="1" rowspan="1">621 (50.28)</td><td align="left" colspan="1" rowspan="1">385 (59.60)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hepatorenal syndrome, n (%)</td><td align="left" colspan="1" rowspan="1">334 (17.76)</td><td align="left" colspan="1" rowspan="1">180 (14.57)</td><td align="left" colspan="1" rowspan="1">154 (23.84)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Malignancy, n (%)</td><td align="left" colspan="1" rowspan="1">360 (19.14)</td><td align="left" colspan="1" rowspan="1">224 (18.14)</td><td align="left" colspan="1" rowspan="1">136 (21.05)</td><td align="left" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Heart failure, n (%)</td><td align="left" colspan="1" rowspan="1">982 (52.21)</td><td align="left" colspan="1" rowspan="1">536 (43.40)</td><td align="left" colspan="1" rowspan="1">446 (69.04)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Atrial fibrillation, n (%)</td><td align="left" colspan="1" rowspan="1">381 (20.26)</td><td align="left" colspan="1" rowspan="1">216 (17.49)</td><td align="left" colspan="1" rowspan="1">165 (25.54)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hepatic encephalopathy, n (%)</td><td align="left" colspan="1" rowspan="1">196 (10.42)</td><td align="left" colspan="1" rowspan="1">127 (10.28)</td><td align="left" colspan="1" rowspan="1">69 (10.68)</td><td align="left" colspan="1" rowspan="1">0.79</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Esophagealvarices with hemorrhage, n (%)</td><td align="left" colspan="1" rowspan="1">217 (11.54)</td><td align="left" colspan="1" rowspan="1">141 (11.42)</td><td align="left" colspan="1" rowspan="1">76 (11.76)</td><td align="left" colspan="1" rowspan="1">0.82</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hepatic failure, n (%)</td><td align="left" colspan="1" rowspan="1">641 (34.08)</td><td align="left" colspan="1" rowspan="1">365 (29.55)</td><td align="left" colspan="1" rowspan="1">276 (42.72)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Septic shock, n (%)</td><td align="left" colspan="1" rowspan="1">631 (33.55)</td><td align="left" colspan="1" rowspan="1">299 (24.21)</td><td align="left" colspan="1" rowspan="1">332 (51.39)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Infections position</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Blood, n (%)</td><td align="left" colspan="1" rowspan="1">74 (3.93)</td><td align="left" colspan="1" rowspan="1">55 (4.45)</td><td align="left" colspan="1" rowspan="1">19 (2.94)</td><td align="left" colspan="1" rowspan="1">0.11</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lung, n (%)</td><td align="left" colspan="1" rowspan="1">619 (32.91)</td><td align="left" colspan="1" rowspan="1">390 (31.58)</td><td align="left" colspan="1" rowspan="1">229 (35.45)</td><td align="left" colspan="1" rowspan="1">0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Abdomen, n (%)</td><td align="left" colspan="1" rowspan="1">359 (19.09)</td><td align="left" colspan="1" rowspan="1">224 (18.14)</td><td align="left" colspan="1" rowspan="1">135 (20.90)</td><td align="left" colspan="1" rowspan="1">0.15</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Urinary, n (%)</td><td align="left" colspan="1" rowspan="1">329 (17.49)</td><td align="left" colspan="1" rowspan="1">216 (17.49)</td><td align="left" colspan="1" rowspan="1">113 (17.49)</td><td align="left" colspan="1" rowspan="1">0.99</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Skin, n (%)</td><td align="left" colspan="1" rowspan="1">85 (4.52)</td><td align="left" colspan="1" rowspan="1">57 (4.62)</td><td align="left" colspan="1" rowspan="1">28 (4.33)</td><td align="left" colspan="1" rowspan="1">0.78</td></tr><tr><td align="left" colspan="5" rowspan="1">Microculture</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Fungal, n (%)</td><td align="left" colspan="1" rowspan="1">372 (19.78)</td><td align="left" colspan="1" rowspan="1">219 (17.73)</td><td align="left" colspan="1" rowspan="1">153 (23.68)</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Bacterial, n (%)</td><td align="left" colspan="1" rowspan="1">1115 (59.28)</td><td align="left" colspan="1" rowspan="1">767 (62.11)</td><td align="left" colspan="1" rowspan="1">348 (53.87)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Bacterial and fungal, n (%)</td><td align="left" colspan="1" rowspan="1">237 (12.60)</td><td align="left" colspan="1" rowspan="1">154 (12.47)</td><td align="left" colspan="1" rowspan="1">83 (12.85)</td><td align="left" colspan="1" rowspan="1">0.81</td></tr><tr><td align="left" colspan="5" rowspan="1">Vital sign</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Heart rate, beats/min</td><td align="left" colspan="1" rowspan="1">94 (80&#8211;107)</td><td align="left" colspan="1" rowspan="1">93 (79&#8211;106)</td><td align="left" colspan="1" rowspan="1">95 (82&#8211;109)</td><td align="left" colspan="1" rowspan="1">0.003</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Systolic blood pressure, mmHg</td><td align="left" colspan="1" rowspan="1">114 (100&#8211;130)</td><td align="left" colspan="1" rowspan="1">116 (101&#8211;134)</td><td align="left" colspan="1" rowspan="1">108 (96&#8211;125)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diastolic blood pressure, mmHg</td><td align="left" colspan="1" rowspan="1">63 (53&#8211;75)</td><td align="left" colspan="1" rowspan="1">63 (55&#8211;75)</td><td align="left" colspan="1" rowspan="1">62 (52&#8211;72)</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean arterial pressure, mmHg</td><td align="left" colspan="1" rowspan="1">80 (70.33-92)</td><td align="left" colspan="1" rowspan="1">81.67 (71.67-94)</td><td align="left" colspan="1" rowspan="1">78 (68.33-89)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Respiratory rate, times/min</td><td align="left" colspan="1" rowspan="1">20 (16&#8211;23)</td><td align="left" colspan="1" rowspan="1">19 (16&#8211;23)</td><td align="left" colspan="1" rowspan="1">21 (17&#8211;25)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">SPO<sub>2</sub>, %</td><td align="left" colspan="1" rowspan="1">98 (95&#8211;100)</td><td align="left" colspan="1" rowspan="1">98 (96&#8211;100)</td><td align="left" colspan="1" rowspan="1">97 (94&#8211;100)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Temperature, &#8451;</td><td align="left" colspan="1" rowspan="1">36.72 (36.44&#8211;37.06)</td><td align="left" colspan="1" rowspan="1">36.78 (36.50-37.17)</td><td align="left" colspan="1" rowspan="1">36.61 (36.33&#8211;36.89)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Laboratory parameters</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Neutrophil cells, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">5.83 (3.48&#8211;10.08)</td><td align="left" colspan="1" rowspan="1">5.11 (3.25&#8211;9.05)</td><td align="left" colspan="1" rowspan="1">7.58 (4.36&#8211;11.78)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lymphocyte cells, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">1.11 (0.71&#8211;1.69)</td><td align="left" colspan="1" rowspan="1">1.14 (0.73&#8211;1.73)</td><td align="left" colspan="1" rowspan="1">1.06 (0.67&#8211;1.6)</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Red blood cells, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">10.9 (7-16.4)</td><td align="left" colspan="1" rowspan="1">10.4 (6.8&#8211;15.6)</td><td align="left" colspan="1" rowspan="1">12.1 (7.6&#8211;18.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;White blood cells, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">2.97 (2.51&#8211;3.5)</td><td align="left" colspan="1" rowspan="1">3.05 (2.6&#8211;3.55)</td><td align="left" colspan="1" rowspan="1">2.81 (2.37&#8211;3.34)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Erythrocyte distribution width, %</td><td align="left" colspan="1" rowspan="1">17 (15.2&#8211;19.1)</td><td align="left" colspan="1" rowspan="1">16.5 (15-18.6)</td><td align="left" colspan="1" rowspan="1">17.7 (15.8&#8211;20)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Platelets, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">102 (66&#8211;154)</td><td align="left" colspan="1" rowspan="1">105 (69&#8211;156)</td><td align="left" colspan="1" rowspan="1">94.5 (61&#8211;152)</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hemoglobin, g/L</td><td align="left" colspan="1" rowspan="1">9.4 (8-10.8)</td><td align="left" colspan="1" rowspan="1">9.5 (8.2&#8211;10.9)</td><td align="left" colspan="1" rowspan="1">9.1 (7.7&#8211;10.6)</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lymphocyte percentage, %</td><td align="left" colspan="1" rowspan="1">9.3 (5.4&#8211;16)</td><td align="left" colspan="1" rowspan="1">10.8 (6&#8211;18)</td><td align="left" colspan="1" rowspan="1">7.6 (4.1&#8211;12)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hematocrit, %</td><td align="left" colspan="1" rowspan="1">28.1 (24.2&#8211;32.6)</td><td align="left" colspan="1" rowspan="1">28.2 (24.7&#8211;32.7)</td><td align="left" colspan="1" rowspan="1">27.4 (23.3&#8211;32.5)</td><td align="left" colspan="1" rowspan="1">0.005</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Creatinine, mg/dL</td><td align="left" colspan="1" rowspan="1">1.3 (0.8&#8211;2.4)</td><td align="left" colspan="1" rowspan="1">1.2 (0.8&#8211;2.1)</td><td align="left" colspan="1" rowspan="1">1.8 (1.1-3)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Blood urea nitrogen, mg/dL</td><td align="left" colspan="1" rowspan="1">28 (16&#8211;49)</td><td align="left" colspan="1" rowspan="1">24 (15&#8211;43)</td><td align="left" colspan="1" rowspan="1">37 (21&#8211;59)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Albumin, g/dL</td><td align="left" colspan="1" rowspan="1">2.9 (2.4&#8211;3.3)</td><td align="left" colspan="1" rowspan="1">2.9 (2.5&#8211;3.3)</td><td align="left" colspan="1" rowspan="1">2.9 (2.4&#8211;3.4)</td><td align="left" colspan="1" rowspan="1">0.85</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Total bilirubin, mg/dL</td><td align="left" colspan="1" rowspan="1">3.4 (1.5&#8211;8.5)</td><td align="left" colspan="1" rowspan="1">2.7 (1.3&#8211;6.2)</td><td align="left" colspan="1" rowspan="1">5.7 (2.1&#8211;15.9)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Direct bilirubin, mg/dL</td><td align="left" colspan="1" rowspan="1">1.8 (0.7&#8211;4.9)</td><td align="left" colspan="1" rowspan="1">1.5 (0.6&#8211;3.8)</td><td align="left" colspan="1" rowspan="1">2.95 (1.1&#8211;8.85)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Aspartate aminotransferase, U/L</td><td align="left" colspan="1" rowspan="1">82 (43-215.5)</td><td align="left" colspan="1" rowspan="1">78 (41&#8211;243)</td><td align="left" colspan="1" rowspan="1">88 (48&#8211;177)</td><td align="left" colspan="1" rowspan="1">0.34</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Alanine aminotransferase, U/L</td><td align="left" colspan="1" rowspan="1">36 (21-92.5)</td><td align="left" colspan="1" rowspan="1">36 (21&#8211;109)</td><td align="left" colspan="1" rowspan="1">37 (22&#8211;71)</td><td align="left" colspan="1" rowspan="1">0.32</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Glucose, mg/dL</td><td align="left" colspan="1" rowspan="1">128 (103&#8211;173)</td><td align="left" colspan="1" rowspan="1">132 (106&#8211;186)</td><td align="left" colspan="1" rowspan="1">122 (96&#8211;153)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Triglyceride, mg/dL</td><td align="left" colspan="1" rowspan="1">115 (80&#8211;173)</td><td align="left" colspan="1" rowspan="1">111.5 (79.5-168.5)</td><td align="left" colspan="1" rowspan="1">126 (80&#8211;197)</td><td align="left" colspan="1" rowspan="1">0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Total cholesterol, mg/dL</td><td align="left" colspan="1" rowspan="1">136 (98&#8211;173)</td><td align="left" colspan="1" rowspan="1">139 (101&#8211;174)</td><td align="left" colspan="1" rowspan="1">130 (90&#8211;173)</td><td align="left" colspan="1" rowspan="1">0.17</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;High density lipoprotein cholesterol, mg/dL</td><td align="left" colspan="1" rowspan="1">41 (25&#8211;55)</td><td align="left" colspan="1" rowspan="1">42 (26&#8211;55)</td><td align="left" colspan="1" rowspan="1">37 (20&#8211;56)</td><td align="left" colspan="1" rowspan="1">0.11</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Low density lipoprotein cholesterol, mg/dL</td><td align="left" colspan="1" rowspan="1">75 (50&#8211;102)</td><td align="left" colspan="1" rowspan="1">76 (50&#8211;102)</td><td align="left" colspan="1" rowspan="1">73 (49&#8211;100)</td><td align="left" colspan="1" rowspan="1">0.38</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Prothrombin time, s</td><td align="left" colspan="1" rowspan="1">19.4 (15.9&#8211;24.4)</td><td align="left" colspan="1" rowspan="1">18.1 (15.2&#8211;22.1)</td><td align="left" colspan="1" rowspan="1">22.4 (18-28.8)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;International normalized ratio</td><td align="left" colspan="1" rowspan="1">1.8 (1.4&#8211;2.3)</td><td align="left" colspan="1" rowspan="1">1.7 (1.4-2)</td><td align="left" colspan="1" rowspan="1">2.1 (1.6&#8211;2.7)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Potassium, mmol/L</td><td align="left" colspan="1" rowspan="1">4.2 (3.7&#8211;4.8)</td><td align="left" colspan="1" rowspan="1">4.2 (3.7&#8211;4.7)</td><td align="left" colspan="1" rowspan="1">4.3 (3.7-5)</td><td align="left" colspan="1" rowspan="1">0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Sodium, mmol/L</td><td align="left" colspan="1" rowspan="1">137 (132&#8211;140)</td><td align="left" colspan="1" rowspan="1">138 (134&#8211;141)</td><td align="left" colspan="1" rowspan="1">136 (130&#8211;140)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Calcium, mg/dL</td><td align="left" colspan="1" rowspan="1">8.2 (7.6&#8211;8.8)</td><td align="left" colspan="1" rowspan="1">8.2 (7.6&#8211;8.8)</td><td align="left" colspan="1" rowspan="1">8.3 (7.6&#8211;8.9)</td><td align="left" colspan="1" rowspan="1">0.36</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anion gap, mmol/L</td><td align="left" colspan="1" rowspan="1">16 (13&#8211;19)</td><td align="left" colspan="1" rowspan="1">15 (12&#8211;18)</td><td align="left" colspan="1" rowspan="1">17 (14&#8211;21)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lactate, mmol/L</td><td align="left" colspan="1" rowspan="1">2.4 (1.6-4)</td><td align="left" colspan="1" rowspan="1">2.2 (1.5&#8211;3.4)</td><td align="left" colspan="1" rowspan="1">3 (2-4.9)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;PH</td><td align="left" colspan="1" rowspan="1">7.36 (7.29&#8211;7.42)</td><td align="left" colspan="1" rowspan="1">7.37 (7.3&#8211;7.42)</td><td align="left" colspan="1" rowspan="1">7.35 (7.26&#8211;7.42)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;FiO2</td><td align="left" colspan="1" rowspan="1">50 (50&#8211;100)</td><td align="left" colspan="1" rowspan="1">50 (40&#8211;90)</td><td align="left" colspan="1" rowspan="1">50 (50&#8211;100)</td><td align="left" colspan="1" rowspan="1">0.10</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;PCO2</td><td align="left" colspan="1" rowspan="1">39 (33&#8211;45)</td><td align="left" colspan="1" rowspan="1">39 (34&#8211;45)</td><td align="left" colspan="1" rowspan="1">37 (31&#8211;44)</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;PaO2</td><td align="left" colspan="1" rowspan="1">83 (49&#8211;157)</td><td align="left" colspan="1" rowspan="1">96 (52&#8211;181)</td><td align="left" colspan="1" rowspan="1">67.5 (45&#8211;113)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Score</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;SOFA</td><td align="left" colspan="1" rowspan="1">4 (1&#8211;7)</td><td align="left" colspan="1" rowspan="1">3 (1&#8211;6)</td><td align="left" colspan="1" rowspan="1">4 (1&#8211;8)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Treatments</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Urinary catheter, n (%)</td><td align="left" colspan="1" rowspan="1">576 (30.62)</td><td align="left" colspan="1" rowspan="1">348 (28.18)</td><td align="left" colspan="1" rowspan="1">228 (35.29)</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Vasopressin, n (%)</td><td align="left" colspan="1" rowspan="1">442 (23.5)</td><td align="left" colspan="1" rowspan="1">173 (14.01)</td><td align="left" colspan="1" rowspan="1">269 (41.64)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ventilation, n (%)</td><td align="left" colspan="1" rowspan="1">1733 (92.13)</td><td align="left" colspan="1" rowspan="1">1127 (91.26)</td><td align="left" colspan="1" rowspan="1">606 (93.81)</td><td align="left" colspan="1" rowspan="1">0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Continuous Renal Replacement Therapy, n (%)</td><td align="left" colspan="1" rowspan="1">403 (21.42)</td><td align="left" colspan="1" rowspan="1">205 (16.60)</td><td align="left" colspan="1" rowspan="1">198 (30.65)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Norepinephrine, n (%)</td><td align="left" colspan="1" rowspan="1">865 (45.99)</td><td align="left" colspan="1" rowspan="1">460 (37.25)</td><td align="left" colspan="1" rowspan="1">405 (62.69)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Clinical outcomes</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LOS-ICU, day</td><td align="left" colspan="1" rowspan="1">4.25 (2.37&#8211;8.63)</td><td align="left" colspan="1" rowspan="1">3.99 (2.28&#8211;8.46)</td><td align="left" colspan="1" rowspan="1">4.73 (2.48&#8211;8.95)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LOS-Hospital, day</td><td align="left" colspan="1" rowspan="1">13.13 (7.42&#8211;23.63)</td><td align="left" colspan="1" rowspan="1">16.17 (8.83&#8211;30.67)</td><td align="left" colspan="1" rowspan="1">9.58 (4.54&#8211;15.33)</td><td align="left" colspan="1" rowspan="1">0.18</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">LOS-ICU</italic> Length of stay in the ICU, <italic toggle="yes">LOS-Hospital</italic>&#160;Length of stay in the hospital</p></table-wrap-foot></table-wrap>
</p><p id="Par46">In terms of laboratory findings, significant differences were observed in white blood cell count, platelet count, hemoglobin, serum creatinine, total bilirubin, glucose, prothrombin time, and lactate levels. Notably, LHR was significantly elevated in the non-survivor group compared with the survivor group (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), suggesting a potential association between LHR and short-term mortality.</p><p id="Par47">Determination of the optimal LHR cutoff and comparison of group characteristics.</p><p id="Par48">Given the significant difference in LHR levels between 28-day survivors and non-survivors, we utilized the surv_cutpoint function in the survminer package to determine the optimal cutoff value for LHR based on 28-day mortality. This method identified 0.12 as the threshold that maximized the log-rank statistic for survival separation (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Patients were subsequently divided into low-LHR (<italic toggle="yes">n</italic>&#8201;=&#8201;1,252) and high-LHR (<italic toggle="yes">n</italic>&#8201;=&#8201;629) groups for further analysis.</p><p id="Par49">As shown in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>, patients in the high-LHR group exhibited a more severe clinical profile, including higher incidence of ascites, hepatorenal syndrome, esophageal variceal bleeding, hepatic failure, and septic shock. Additionally, they had significantly elevated heart and respiratory rates and lower blood pressure and temperature. Laboratory markers, including hematologic, hepatic, renal, and coagulation parameters, also differed significantly between the two groups.</p><p id="Par50">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Baseline characteristics of patients with cirrhosis and sepsis stratified by LHR using the optimal cutoff value</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="left" colspan="1" rowspan="1">Overall (<italic toggle="yes">n</italic>&#8201;=&#8201;1881)</th><th align="left" colspan="1" rowspan="1">Lower LHR (<italic toggle="yes">n</italic>&#8201;=&#8201;1252)</th><th align="left" colspan="1" rowspan="1">Higher LHR (<italic toggle="yes">n</italic>&#8201;=&#8201;629)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">LHR</td><td align="left" colspan="1" rowspan="1">0.09 (0.06&#8211;0.15)</td><td align="left" colspan="1" rowspan="1">0.07 (0.05&#8211;0.09)</td><td align="left" colspan="1" rowspan="1">0.19 (0.15&#8211;0.27)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Demographics</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Age, years</td><td align="left" colspan="1" rowspan="1">58 (50&#8211;65)</td><td align="left" colspan="1" rowspan="1">58 (51&#8211;65)</td><td align="left" colspan="1" rowspan="1">57 (49&#8211;64)</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Men, n (%)</td><td align="left" colspan="1" rowspan="1">1208 (64.22)</td><td align="left" colspan="1" rowspan="1">792 (63.26)</td><td align="left" colspan="1" rowspan="1">416 (66.14)</td><td align="left" colspan="1" rowspan="1">0.22</td></tr><tr><td align="left" colspan="5" rowspan="1">Ethnicity, n (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Asian population</td><td align="left" colspan="1" rowspan="1">46 (2.45)</td><td align="left" colspan="1" rowspan="1">27 (2.157)</td><td align="left" colspan="1" rowspan="1">19 (3.021)</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;White population</td><td align="left" colspan="1" rowspan="1">1183 (62.89)</td><td align="left" colspan="1" rowspan="1">817 (65.26)</td><td align="left" colspan="1" rowspan="1">366 (58.19)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Black population</td><td align="left" colspan="1" rowspan="1">138 (7.34)</td><td align="left" colspan="1" rowspan="1">90 (7.19)</td><td align="left" colspan="1" rowspan="1">48 (7.63)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Others</td><td align="left" colspan="1" rowspan="1">514 (27.33)</td><td align="left" colspan="1" rowspan="1">318 (25.40)</td><td align="left" colspan="1" rowspan="1">196 (31.16)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Causes of liver cirrhosis, n (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Alcohol</td><td align="left" colspan="1" rowspan="1">839 (44.60)</td><td align="left" colspan="1" rowspan="1">546 (43.61)</td><td align="left" colspan="1" rowspan="1">293 (46.58)</td><td align="left" colspan="1" rowspan="1">0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Viral</td><td align="left" colspan="1" rowspan="1">523 (27.80)</td><td align="left" colspan="1" rowspan="1">342 (27.32)</td><td align="left" colspan="1" rowspan="1">181 (28.78)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Biliary</td><td align="left" colspan="1" rowspan="1">38 (2.02)</td><td align="left" colspan="1" rowspan="1">31 (2.48)</td><td align="left" colspan="1" rowspan="1">7 (1.11)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Others</td><td align="left" colspan="1" rowspan="1">481 (25.57)</td><td align="left" colspan="1" rowspan="1">333 (26.60)</td><td align="left" colspan="1" rowspan="1">148 (23.53)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Comorbidities</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hypertension, n (%)</td><td align="left" colspan="1" rowspan="1">1243 (66.08)</td><td align="left" colspan="1" rowspan="1">827 (66.05)</td><td align="left" colspan="1" rowspan="1">416 (66.14)</td><td align="left" colspan="1" rowspan="1">0.97</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diabetes mellitus, n (%)</td><td align="left" colspan="1" rowspan="1">580 (30.83)</td><td align="left" colspan="1" rowspan="1">379 (30.27)</td><td align="left" colspan="1" rowspan="1">201 (31.96)</td><td align="left" colspan="1" rowspan="1">0.46</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Chronic obstructive pulmonary disease, n (%)</td><td align="left" colspan="1" rowspan="1">134 (7.12)</td><td align="left" colspan="1" rowspan="1">92 (7.35)</td><td align="left" colspan="1" rowspan="1">42 (6.68)</td><td align="left" colspan="1" rowspan="1">0.59</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Coronary heart disease, n (%)</td><td align="left" colspan="1" rowspan="1">301 (16.00)</td><td align="left" colspan="1" rowspan="1">240 (19.17)</td><td align="left" colspan="1" rowspan="1">61 (9.70)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Myocardial infarction, n (%)</td><td align="left" colspan="1" rowspan="1">231 (12.28)</td><td align="left" colspan="1" rowspan="1">163 (13.02)</td><td align="left" colspan="1" rowspan="1">68 (10.81)</td><td align="left" colspan="1" rowspan="1">0.17</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ascites, n (%)</td><td align="left" colspan="1" rowspan="1">1006 (53.48)</td><td align="left" colspan="1" rowspan="1">630 (50.32)</td><td align="left" colspan="1" rowspan="1">376 (59.78)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hepatorenal syndrome, n (%)</td><td align="left" colspan="1" rowspan="1">334 (17.76)</td><td align="left" colspan="1" rowspan="1">198 (15.81)</td><td align="left" colspan="1" rowspan="1">136 (21.62)</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Malignancy, n (%)</td><td align="left" colspan="1" rowspan="1">360 (19.14)</td><td align="left" colspan="1" rowspan="1">236 (18.85)</td><td align="left" colspan="1" rowspan="1">124 (19.71)</td><td align="left" colspan="1" rowspan="1">0.65</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Heart failure, n (%)</td><td align="left" colspan="1" rowspan="1">982 (52.21)</td><td align="left" colspan="1" rowspan="1">626 (50.00)</td><td align="left" colspan="1" rowspan="1">356 (56.60)</td><td align="left" colspan="1" rowspan="1">0.007</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Atrial fibrillation, n (%)</td><td align="left" colspan="1" rowspan="1">381 (20.26)</td><td align="left" colspan="1" rowspan="1">261 (20.85)</td><td align="left" colspan="1" rowspan="1">120 (19.08)</td><td align="left" colspan="1" rowspan="1">0.37</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hepatic encephalopathy, n (%)</td><td align="left" colspan="1" rowspan="1">196 (10.42)</td><td align="left" colspan="1" rowspan="1">145 (11.58)</td><td align="left" colspan="1" rowspan="1">51 (8.11)</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Esophagealvarices with hemorrhage, n (%)</td><td align="left" colspan="1" rowspan="1">217 (11.54)</td><td align="left" colspan="1" rowspan="1">131 (10.46)</td><td align="left" colspan="1" rowspan="1">86 (13.67)</td><td align="left" colspan="1" rowspan="1">0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hepatic failure, n (%)</td><td align="left" colspan="1" rowspan="1">641 (34.08)</td><td align="left" colspan="1" rowspan="1">369 (29.47)</td><td align="left" colspan="1" rowspan="1">272 (43.24)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Septic shock, n (%)</td><td align="left" colspan="1" rowspan="1">631 (33.55)</td><td align="left" colspan="1" rowspan="1">373 (29.79)</td><td align="left" colspan="1" rowspan="1">258 (41.02)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Infections position</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Blood, n (%)</td><td align="left" colspan="1" rowspan="1">74 (3.93)</td><td align="left" colspan="1" rowspan="1">48 (3.83)</td><td align="left" colspan="1" rowspan="1">26 (4.13)</td><td align="left" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lung, n (%)</td><td align="left" colspan="1" rowspan="1">619 (32.91)</td><td align="left" colspan="1" rowspan="1">426 (34.03)</td><td align="left" colspan="1" rowspan="1">193 (30.68)</td><td align="left" colspan="1" rowspan="1">0.14</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Abdomen, n (%)</td><td align="left" colspan="1" rowspan="1">359 (19.09)</td><td align="left" colspan="1" rowspan="1">212 (16.93)</td><td align="left" colspan="1" rowspan="1">147 (23.37)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Urinary, n (%)</td><td align="left" colspan="1" rowspan="1">329 (17.49)</td><td align="left" colspan="1" rowspan="1">231 (18.45)</td><td align="left" colspan="1" rowspan="1">98 (15.58)</td><td align="left" colspan="1" rowspan="1">0.12</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Skin, n (%)</td><td align="left" colspan="1" rowspan="1">85 (4.52)</td><td align="left" colspan="1" rowspan="1">55 (4.39)</td><td align="left" colspan="1" rowspan="1">30 (4.77)</td><td align="left" colspan="1" rowspan="1">0.71</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mixed infections, n (%)</td><td align="left" colspan="1" rowspan="1">39 (2.0)</td><td align="left" colspan="1" rowspan="1">22 (1.7)</td><td align="left" colspan="1" rowspan="1">17 (2.7)</td><td align="left" colspan="1" rowspan="1">0.68</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Unkonwn,, n (%)</td><td align="left" colspan="1" rowspan="1">87 (4.6)</td><td align="left" colspan="1" rowspan="1">49 (3.9)</td><td align="left" colspan="1" rowspan="1">38 (6.0)</td><td align="left" colspan="1" rowspan="1">0.09</td></tr><tr><td align="left" colspan="5" rowspan="1">Microculture</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Fungal, n (%)</td><td align="left" colspan="1" rowspan="1">372 (19.78)</td><td align="left" colspan="1" rowspan="1">243 (19.41)</td><td align="left" colspan="1" rowspan="1">129 (20.51)</td><td align="left" colspan="1" rowspan="1">0.57</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Bacterial, n (%)</td><td align="left" colspan="1" rowspan="1">1115 (59.28)</td><td align="left" colspan="1" rowspan="1">735 (58.71)</td><td align="left" colspan="1" rowspan="1">380 (60.41)</td><td align="left" colspan="1" rowspan="1">0.48</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Bacterial and fungal, n (%)</td><td align="left" colspan="1" rowspan="1">237 (12.60)</td><td align="left" colspan="1" rowspan="1">151 (12.06)</td><td align="left" colspan="1" rowspan="1">86 (13.67)</td><td align="left" colspan="1" rowspan="1">0.32</td></tr><tr><td align="left" colspan="5" rowspan="1">Vital signs</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Heart rate, beats/min</td><td align="left" colspan="1" rowspan="1">94 (80&#8211;107)</td><td align="left" colspan="1" rowspan="1">91 (78&#8211;104)</td><td align="left" colspan="1" rowspan="1">98 (84&#8211;113)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Systolic blood pressure, mmHg</td><td align="left" colspan="1" rowspan="1">114 (100&#8211;130)</td><td align="left" colspan="1" rowspan="1">115 (101&#8211;132)</td><td align="left" colspan="1" rowspan="1">110 (96&#8211;128)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diastolic blood pressure, mmHg</td><td align="left" colspan="1" rowspan="1">63 (53&#8211;75)</td><td align="left" colspan="1" rowspan="1">65 (55&#8211;77)</td><td align="left" colspan="1" rowspan="1">60 (51&#8211;69)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean arterial pressure, mmHg</td><td align="left" colspan="1" rowspan="1">80 (70.33-92)</td><td align="left" colspan="1" rowspan="1">82 (71.67&#8211;94.33)</td><td align="left" colspan="1" rowspan="1">77 (68&#8211;88)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Respiratory rate, times/min</td><td align="left" colspan="1" rowspan="1">20 (16&#8211;23)</td><td align="left" colspan="1" rowspan="1">19 (16&#8211;23)</td><td align="left" colspan="1" rowspan="1">20 (17&#8211;24)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;SPO<sub>2</sub>, %</td><td align="left" colspan="1" rowspan="1">98 (95&#8211;100)</td><td align="left" colspan="1" rowspan="1">98 (95&#8211;100)</td><td align="left" colspan="1" rowspan="1">98 (95&#8211;100)</td><td align="left" colspan="1" rowspan="1">0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Temperature, &#8451;</td><td align="left" colspan="1" rowspan="1">36.72 (36.44&#8211;37.06)</td><td align="left" colspan="1" rowspan="1">36.78 (36.44&#8211;37.11)</td><td align="left" colspan="1" rowspan="1">36.67 (36.39-37)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Laboratory parameters</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Neutrophil cells, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">5.83 (3.48&#8211;10.08)</td><td align="left" colspan="1" rowspan="1">5.75 (3.47&#8211;9.69)</td><td align="left" colspan="1" rowspan="1">5.97 (3.56&#8211;10.38)</td><td align="left" colspan="1" rowspan="1">0.12</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lymphocyte cells, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">1.11 (0.71&#8211;1.69)</td><td align="left" colspan="1" rowspan="1">1.11 (0.71&#8211;1.73)</td><td align="left" colspan="1" rowspan="1">1.12 (0.7&#8211;1.64)</td><td align="left" colspan="1" rowspan="1">0.51</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Red blood cells, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">10.9 (7-16.4)</td><td align="left" colspan="1" rowspan="1">10.7 (7-15.7)</td><td align="left" colspan="1" rowspan="1">11.2 (7-18.3)</td><td align="left" colspan="1" rowspan="1">0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;White blood cells, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">2.97 (2.51&#8211;3.5)</td><td align="left" colspan="1" rowspan="1">3.09 (2.63&#8211;3.63)</td><td align="left" colspan="1" rowspan="1">2.72 (2.29&#8211;3.2)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Erythrocyte distribution width, %</td><td align="left" colspan="1" rowspan="1">17 (15.2&#8211;19.1)</td><td align="left" colspan="1" rowspan="1">16.8 (15.1&#8211;18.8)</td><td align="left" colspan="1" rowspan="1">17.3 (15.5&#8211;19.7)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Platelets, 10<sup>9</sup>/L</td><td align="left" colspan="1" rowspan="1">102 (66&#8211;154)</td><td align="left" colspan="1" rowspan="1">107 (71&#8211;162)</td><td align="left" colspan="1" rowspan="1">90 (58&#8211;140)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hemoglobin, g/L</td><td align="left" colspan="1" rowspan="1">9.4 (8-10.8)</td><td align="left" colspan="1" rowspan="1">9.7 (8.3&#8211;11.1)</td><td align="left" colspan="1" rowspan="1">8.7 (7.4&#8211;10.1)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lymphocyte percentage, %</td><td align="left" colspan="1" rowspan="1">9.3 (5.4&#8211;16)</td><td align="left" colspan="1" rowspan="1">9.5 (5.7&#8211;16.1)</td><td align="left" colspan="1" rowspan="1">9 (5-14.9)</td><td align="left" colspan="1" rowspan="1">0.10</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hematocrit, %</td><td align="left" colspan="1" rowspan="1">28.1 (24.2&#8211;32.6)</td><td align="left" colspan="1" rowspan="1">29.05 (25.2&#8211;33.7)</td><td align="left" colspan="1" rowspan="1">26.3 (22.5&#8211;30.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Creatinine, mg/dL</td><td align="left" colspan="1" rowspan="1">1.3 (0.8&#8211;2.4)</td><td align="left" colspan="1" rowspan="1">1.2 (0.8&#8211;2.2)</td><td align="left" colspan="1" rowspan="1">1.5 (0.9&#8211;2.6)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Blood urea nitrogen, mg/dL</td><td align="left" colspan="1" rowspan="1">28 (16&#8211;49)</td><td align="left" colspan="1" rowspan="1">27.5 (16&#8211;50)</td><td align="left" colspan="1" rowspan="1">29 (16&#8211;48)</td><td align="left" colspan="1" rowspan="1">0.85</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Albumin, g/dL</td><td align="left" colspan="1" rowspan="1">2.9 (2.4&#8211;3.3)</td><td align="left" colspan="1" rowspan="1">2.9 (2.5&#8211;3.3)</td><td align="left" colspan="1" rowspan="1">2.8 (2.4&#8211;3.4)</td><td align="left" colspan="1" rowspan="1">0.42</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Total bilirubin, mg/dL</td><td align="left" colspan="1" rowspan="1">3.4 (1.5&#8211;8.5)</td><td align="left" colspan="1" rowspan="1">2.7 (1.3-7)</td><td align="left" colspan="1" rowspan="1">4.55 (2.3&#8211;10.1)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Direct bilirubin, mg/dL</td><td align="left" colspan="1" rowspan="1">1.8 (0.7&#8211;4.9)</td><td align="left" colspan="1" rowspan="1">1.6 (0.7&#8211;4.4)</td><td align="left" colspan="1" rowspan="1">2.2 (0.8&#8211;5.9)</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Aspartate aminotransferase, U/L</td><td align="left" colspan="1" rowspan="1">82 (43-215.5)</td><td align="left" colspan="1" rowspan="1">70 (40&#8211;152)</td><td align="left" colspan="1" rowspan="1">116 (55&#8211;445)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Alanine aminotransferase, U/L</td><td align="left" colspan="1" rowspan="1">36 (21-92.5)</td><td align="left" colspan="1" rowspan="1">33 (20&#8211;73)</td><td align="left" colspan="1" rowspan="1">44 (25-163.5)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Glucose, mg/dL</td><td align="left" colspan="1" rowspan="1">128 (103&#8211;173)</td><td align="left" colspan="1" rowspan="1">125 (104&#8211;163)</td><td align="left" colspan="1" rowspan="1">136 (101&#8211;195)</td><td align="left" colspan="1" rowspan="1">0.003</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Triglyceride, mg/dL</td><td align="left" colspan="1" rowspan="1">115 (80&#8211;173)</td><td align="left" colspan="1" rowspan="1">115.5 (79-172.5)</td><td align="left" colspan="1" rowspan="1">113 (81&#8211;174)</td><td align="left" colspan="1" rowspan="1">0.66</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Total cholesterol, mg/dL</td><td align="left" colspan="1" rowspan="1">136 (98&#8211;173)</td><td align="left" colspan="1" rowspan="1">136 (100&#8211;173)</td><td align="left" colspan="1" rowspan="1">137 (94&#8211;176)</td><td align="left" colspan="1" rowspan="1">0.77</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;High density lipoprotein cholesterol, mg/dL</td><td align="left" colspan="1" rowspan="1">41 (25&#8211;55)</td><td align="left" colspan="1" rowspan="1">41 (27&#8211;55)</td><td align="left" colspan="1" rowspan="1">40 (22&#8211;57)</td><td align="left" colspan="1" rowspan="1">0.33</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Low density lipoprotein cholesterol, mg/dL</td><td align="left" colspan="1" rowspan="1">75 (50&#8211;102)</td><td align="left" colspan="1" rowspan="1">76 (50.5&#8211;103)</td><td align="left" colspan="1" rowspan="1">74 (47.5&#8211;98.5)</td><td align="left" colspan="1" rowspan="1">0.32</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Prothrombin time, s</td><td align="left" colspan="1" rowspan="1">19.4 (15.9&#8211;24.4)</td><td align="left" colspan="1" rowspan="1">18 (15.2&#8211;22.7)</td><td align="left" colspan="1" rowspan="1">21.7 (18.4&#8211;28)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;International normalized ratio</td><td align="left" colspan="1" rowspan="1">1.8 (1.4&#8211;2.3)</td><td align="left" colspan="1" rowspan="1">1.6 (1.4&#8211;2.1)</td><td align="left" colspan="1" rowspan="1">2 (1.7&#8211;2.6)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Potassium, mmol/L</td><td align="left" colspan="1" rowspan="1">4.2 (3.7&#8211;4.8)</td><td align="left" colspan="1" rowspan="1">4.2 (3.7&#8211;4.7)</td><td align="left" colspan="1" rowspan="1">4.3 (3.8-5)</td><td align="left" colspan="1" rowspan="1">0.006</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Sodium, mmol/L</td><td align="left" colspan="1" rowspan="1">137 (132&#8211;140)</td><td align="left" colspan="1" rowspan="1">137 (133&#8211;140)</td><td align="left" colspan="1" rowspan="1">137 (131&#8211;140)</td><td align="left" colspan="1" rowspan="1">0.30</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Calcium, mg/dL</td><td align="left" colspan="1" rowspan="1">8.2 (7.6&#8211;8.8)</td><td align="left" colspan="1" rowspan="1">8.2 (7.6&#8211;8.8)</td><td align="left" colspan="1" rowspan="1">8.3 (7.5-9)</td><td align="left" colspan="1" rowspan="1">0.052</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anion gap, mmol/L</td><td align="left" colspan="1" rowspan="1">16 (13&#8211;19)</td><td align="left" colspan="1" rowspan="1">14 (12&#8211;17)</td><td align="left" colspan="1" rowspan="1">19 (15&#8211;23)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lactate, mmol/L</td><td align="left" colspan="1" rowspan="1">2.4 (1.6-4)</td><td align="left" colspan="1" rowspan="1">1.9 (1.4&#8211;2.4)</td><td align="left" colspan="1" rowspan="1">4.9 (3.9&#8211;7.3)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;PH</td><td align="left" colspan="1" rowspan="1">7.36 (7.29&#8211;7.42)</td><td align="left" colspan="1" rowspan="1">7.37 (7.31&#8211;7.43)</td><td align="left" colspan="1" rowspan="1">7.33 (7.24&#8211;7.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;FiO2</td><td align="left" colspan="1" rowspan="1">50 (50&#8211;100)</td><td align="left" colspan="1" rowspan="1">50 (43&#8211;94)</td><td align="left" colspan="1" rowspan="1">50 (50&#8211;100)</td><td align="left" colspan="1" rowspan="1">0.33</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;PCO2</td><td align="left" colspan="1" rowspan="1">39 (33&#8211;45)</td><td align="left" colspan="1" rowspan="1">39 (34&#8211;45)</td><td align="left" colspan="1" rowspan="1">37 (31&#8211;43)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;PaO2</td><td align="left" colspan="1" rowspan="1">83 (49&#8211;157)</td><td align="left" colspan="1" rowspan="1">82 (49-150.5)</td><td align="left" colspan="1" rowspan="1">86 (49&#8211;179)</td><td align="left" colspan="1" rowspan="1">0.12</td></tr><tr><td align="left" colspan="5" rowspan="1">Score</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;SOFA</td><td align="left" colspan="1" rowspan="1">4 (1&#8211;7)</td><td align="left" colspan="1" rowspan="1">3 (1&#8211;6)</td><td align="left" colspan="1" rowspan="1">5 (1&#8211;8)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Treatments</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Urinary catheter, n (%)</td><td align="left" colspan="1" rowspan="1">576 (30.62)</td><td align="left" colspan="1" rowspan="1">349 (27.88)</td><td align="left" colspan="1" rowspan="1">227 (36.09)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Vasopressin, n (%)</td><td align="left" colspan="1" rowspan="1">442 (23.5)</td><td align="left" colspan="1" rowspan="1">231 (18.45)</td><td align="left" colspan="1" rowspan="1">211 (33.55)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ventilation, n (%)</td><td align="left" colspan="1" rowspan="1">1733 (92.13)</td><td align="left" colspan="1" rowspan="1">1146 (91.53)</td><td align="left" colspan="1" rowspan="1">587 (93.32)</td><td align="left" colspan="1" rowspan="1">0.17</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Continuous Renal Replacement Therapy, n (%)</td><td align="left" colspan="1" rowspan="1">403 (21.42)</td><td align="left" colspan="1" rowspan="1">217 (17.33)</td><td align="left" colspan="1" rowspan="1">186 (29.57)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Norepinephrine, n (%)</td><td align="left" colspan="1" rowspan="1">865 (45.99)</td><td align="left" colspan="1" rowspan="1">522 (41.69)</td><td align="left" colspan="1" rowspan="1">343 (54.53)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Clinical outcomes</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LOS-ICU, day</td><td align="left" colspan="1" rowspan="1">4.25 (2.37&#8211;8.63)</td><td align="left" colspan="1" rowspan="1">4.56 (2.42&#8211;8.50)</td><td align="left" colspan="1" rowspan="1">4.00 (2.25&#8211;8.96)</td><td align="left" colspan="1" rowspan="1">0.07</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LOS-Hospital, day</td><td align="left" colspan="1" rowspan="1">13.13 (7.42&#8211;23.63)</td><td align="left" colspan="1" rowspan="1">13.25 (7.63&#8211;23.48)</td><td align="left" colspan="1" rowspan="1">12.92 (6.50-23.71)</td><td align="left" colspan="1" rowspan="1">0.37</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ICU mortality, n (%)</td><td align="left" colspan="1" rowspan="1">424 (22.54)</td><td align="left" colspan="1" rowspan="1">199 (15.89)</td><td align="left" colspan="1" rowspan="1">225 (35.77)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hospital mortality, n (%)</td><td align="left" colspan="1" rowspan="1">632 (33.6)</td><td align="left" colspan="1" rowspan="1">339 (27.08)</td><td align="left" colspan="1" rowspan="1">293 (46.58)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;14-day mortality, n (%)</td><td align="left" colspan="1" rowspan="1">433 (23.02)</td><td align="left" colspan="1" rowspan="1">222 (17.73)</td><td align="left" colspan="1" rowspan="1">211 (33.55)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;28-day mortality, n (%)</td><td align="left" colspan="1" rowspan="1">646 (34.34)</td><td align="left" colspan="1" rowspan="1">350 (27.96)</td><td align="left" colspan="1" rowspan="1">296 (47.06)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;90-day mortality, n (%)</td><td align="left" colspan="1" rowspan="1">835 (44.39)</td><td align="left" colspan="1" rowspan="1">475 (37.94)</td><td align="left" colspan="1" rowspan="1">360 (57.23)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>Infection sites were classified based on microbiological culture results and clinical diagnostic information from the MIMIC-IV database</p><p>&#8226; Mixed infections&#160;refer to cases where infections were concurrently identified at two or more distinct anatomical sites</p><p>&#8226; Unknown&#160;includes patients who had evidence of infection but lacked clear documentation of the infection site, either due to negative cultures or unspecified diagnostic records</p><p><italic toggle="yes">LHR</italic> Lactate to hematocrit ratio, <italic toggle="yes">SOFA</italic> Sequential organ failure assessment</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Relationships between LHR and clinical outcomes</title><p id="Par51">Cox regression model (Model 1), higher LHR values were strongly associated with increased risks of 14-day (HR&#8201;=&#8201;2.18, 95% CI: 1.81&#8211;2.64, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), 28-day (HR&#8201;=&#8201;2.02, 95% CI: 1.73&#8211;2.36, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), and 90-day (HR&#8201;=&#8201;1.88, 95% CI: 1.64&#8211;2.16, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) all-cause mortality.</p><p id="Par52">After adjusting for age, sex, and ethnicity in Model 2, the results consistently demonstrated that patients with higher LHR values remained at an elevated risks of 14-day (HR&#8201;=&#8201;2.21, 95% CI: 1.83&#8211;2.68, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), 28-day (HR&#8201;=&#8201;2.04, 95% CI: 1.75&#8211;2.38, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), and 90-day (HR&#8201;=&#8201;1.90, 95% CI: 1.65&#8211;2.18, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) all-cause mortality.</p><p id="Par53">In Model 3, which was additionally adjusted for confounding factors, including SOFA score, serum creatinine level, white blood cell count, platelet count, hypertension, heart failure, respiratory failure, diabetes, vasopressin use, and continuous renal replacement therapy, higher LHR was significantly associated with an increased risk of all-cause mortality (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par54">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Cox proportional hazard ratios (HR) for all-cause mortality</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Model 1</th><th align="left" colspan="2" rowspan="1">Model 2</th><th align="left" colspan="2" rowspan="1">Model 3</th></tr><tr><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">14-day all-cause mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LHR (continuous)<sup>*</sup></td><td align="left" colspan="1" rowspan="1">1.29 (1.23&#8211;1.35)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.30 (1.24&#8211;1.35)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.23 (1.17&#8211;1.30)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lower LHR</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Higher LHR</td><td align="left" colspan="1" rowspan="1">2.18 (1.81&#8211;2.64)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">2.21 (1.83&#8211;2.68)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.88 (1.55&#8211;2.30)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">28-day all-cause mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LHR (continuous)<sup>*</sup></td><td align="left" colspan="1" rowspan="1">1.27 (1.22&#8211;1.32)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.28 (1.23&#8211;1.33)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.20 (1.15&#8211;1.26)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lower LHR</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Higher LHR</td><td align="left" colspan="1" rowspan="1">2.02 (1.73&#8211;2.36)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">2.04 (1.75&#8211;2.38)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.74 (1.48&#8211;2.04)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">90-day all-cause mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LHR (continuous)<sup>*</sup></td><td align="left" colspan="1" rowspan="1">1.26 (1.22&#8211;1.31)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.27 (1.23&#8211;1.32)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.20 (1.15&#8211;1.25)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lower LHR</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Higher LHR</td><td align="left" colspan="1" rowspan="1">1.88 (1.64&#8211;2.16)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.90 (1.65&#8211;2.18)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.66 (1.44&#8211;1.92)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>Model 1: Unadjusted</p><p>Model 2: Adjusted age, gender, and ethnicity</p><p>Model 3: Adjusted age, gender, ethnicity, sequential organ failure assessment, serum creatinine, white blood cells, platelets, hypertension, heart failure, respiratory failure, diabetes, vasopressin, and continuous renal replacement therapy</p><p><sup>*</sup>LHR/0.1</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Kaplan&#8211;Meier survival curves for critically ill patients with cirrhosis and sepsis</title><p id="Par55">In the present study, 424 patients (22.54%) died during their ICU stay and 632 patients (33.6%) died during hospitalization. Additionally, 433 patients (23.02%) died within 14 days of admission, 646 (34.34%) within 28 days, and 835 (44.39%) within 90 days. The Kaplan&#8211;Meier survival curves revealed significantly higher ICU, in-hospital, and 14-day, 28-day, and 90-day all-cause mortality in patients with higher LHR values than those with lower LHR values (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>, all log-rank <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p><p id="Par56">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Kaplan&#8211;Meier curves and cumulative incidence of ICU <bold>A</bold>, in-hospital <bold>B</bold>, 14-day <bold>C</bold>, 28-day <bold>D</bold>, and 90-day <bold>E</bold>&#160;all-cause mortality stratified by LHR groups</p></caption><graphic id="d33e2942" position="float" orientation="portrait" xlink:href="12879_2025_11527_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec13"><title>Detection of nonlinear relationships</title><p id="Par57">RCS analysis further revealed a nonlinear relationship between LHR and 14-day (<italic toggle="yes">P</italic> for no-linear&#8201;&lt;&#8201;0.001), 28-day (<italic toggle="yes">P</italic> for no-linear&#8201;&lt;&#8201;0.001), and 90-day (<italic toggle="yes">P</italic> for no-linear&#8201;&lt;&#8201;0.001) all-cause mortality in critically ill patients with cirrhosis and sepsis (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par58">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Restricted cubic spline regression analysis of LHR with 14-day <bold>A</bold>, 28-day <bold>B</bold>, and 90-day <bold>C</bold>&#160;all-cause mortality in patients with cirrhosis and combined sepsis. 14-day all-cause mortality: <italic toggle="yes">P</italic> for no-linear&#8201;&lt;&#8201;0.001; 28-day all-cause mortality: <italic toggle="yes">P</italic> for no-linear&#8201;&lt;&#8201;0.001; 90-day all-cause mortality: <italic toggle="yes">P</italic> for no-linear&#8201;&lt;&#8201;0.001</p></caption><graphic id="d33e2988" position="float" orientation="portrait" xlink:href="12879_2025_11527_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec14"><title>Predictive value of LHR for all-cause mortality in patients with cirrhosis and sepsis</title><p id="Par59">ROC curves of the LHR, BUN, serum creatinine, albumin, and SOFA scores to evaluate their predictive values for short- and long-term all-cause mortality in patients with cirrhosis and sepsis demonstrated the superior prognostic performance of LHR compared with other indicators (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). For instance, the AUC of LHR in predicting 14-day all-cause mortality after admission was 65.07% (95% CI: 62.00&#8211;68.13), compared to 58.76% for BUN (95% CI: 55.49&#8211;62.02), 62.45% for serum creatinine (95% CI: 59.35&#8211;65.54)], 49.97% for albumin (95% CI: 46.50&#8211;53.44)], and 53.47% for SOFA score (95% CI: 50.09&#8211;56.85) (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>).</p><p id="Par60">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Receiver operating characteristic curves assesses the predictive capability of the LHR for 14-day <bold>A</bold>, 28-day <bold>B</bold>, and 90-day <bold>C</bold>&#160;all-cause mortality</p></caption><graphic id="d33e3018" position="float" orientation="portrait" xlink:href="12879_2025_11527_Fig5_HTML.jpg"/></fig>
</p><p id="Par61">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Information of ROC curves in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">AUC (%)</th><th align="left" colspan="1" rowspan="1">95% CI (%)</th><th align="left" colspan="1" rowspan="1">Threshold</th><th align="left" colspan="1" rowspan="1">Sensitivity</th><th align="left" colspan="1" rowspan="1">Specificity</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">14-day all-cause mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LHR</td><td align="left" colspan="1" rowspan="1">65.07</td><td align="left" colspan="1" rowspan="1">62.00-68.13</td><td align="left" colspan="1" rowspan="1">0.090</td><td align="left" colspan="1" rowspan="1">0.577</td><td align="left" colspan="1" rowspan="1">0.642</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;BUN</td><td align="left" colspan="1" rowspan="1">58.76</td><td align="left" colspan="1" rowspan="1">55.49&#8211;62.02</td><td align="left" colspan="1" rowspan="1">33.500</td><td align="left" colspan="1" rowspan="1">0.629</td><td align="left" colspan="1" rowspan="1">0.538</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ALB</td><td align="left" colspan="1" rowspan="1">49.97</td><td align="left" colspan="1" rowspan="1">46.50-53.44</td><td align="left" colspan="1" rowspan="1">3.350</td><td align="left" colspan="1" rowspan="1">0.783</td><td align="left" colspan="1" rowspan="1">0.265</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Crea</td><td align="left" colspan="1" rowspan="1">62.45</td><td align="left" colspan="1" rowspan="1">59.35&#8211;65.54</td><td align="left" colspan="1" rowspan="1">1.350</td><td align="left" colspan="1" rowspan="1">0.555</td><td align="left" colspan="1" rowspan="1">0.661</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;SOFA</td><td align="left" colspan="1" rowspan="1">53.47</td><td align="left" colspan="1" rowspan="1">50.09&#8211;56.85</td><td align="left" colspan="1" rowspan="1">6.500</td><td align="left" colspan="1" rowspan="1">0.765</td><td align="left" colspan="1" rowspan="1">0.307</td></tr><tr><td align="left" colspan="6" rowspan="1">28-day all-cause mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LHR</td><td align="left" colspan="1" rowspan="1">64.21</td><td align="left" colspan="1" rowspan="1">61.49&#8211;66.93</td><td align="left" colspan="1" rowspan="1">0.088</td><td align="left" colspan="1" rowspan="1">0.590</td><td align="left" colspan="1" rowspan="1">0.625</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;BUN</td><td align="left" colspan="1" rowspan="1">61.71</td><td align="left" colspan="1" rowspan="1">58.90-64.52</td><td align="left" colspan="1" rowspan="1">31.500</td><td align="left" colspan="1" rowspan="1">0.639</td><td align="left" colspan="1" rowspan="1">0.590</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ALB</td><td align="left" colspan="1" rowspan="1">50.28</td><td align="left" colspan="1" rowspan="1">47.28&#8211;53.29</td><td align="left" colspan="1" rowspan="1">3.350</td><td align="left" colspan="1" rowspan="1">0.793</td><td align="left" colspan="1" rowspan="1">0.269</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Crea</td><td align="left" colspan="1" rowspan="1">63.56</td><td align="left" colspan="1" rowspan="1">60.82&#8211;66.30</td><td align="left" colspan="1" rowspan="1">1.550</td><td align="left" colspan="1" rowspan="1">0.661</td><td align="left" colspan="1" rowspan="1">0.576</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;SOFA</td><td align="left" colspan="1" rowspan="1">55.58</td><td align="left" colspan="1" rowspan="1">52.67&#8211;58.50</td><td align="left" colspan="1" rowspan="1">6.500</td><td align="left" colspan="1" rowspan="1">0.788</td><td align="left" colspan="1" rowspan="1">0.327</td></tr><tr><td align="left" colspan="6" rowspan="1">90-day all-cause mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LHR</td><td align="left" colspan="1" rowspan="1">63.76</td><td align="left" colspan="1" rowspan="1">61.16&#8211;66.36</td><td align="left" colspan="1" rowspan="1">0.095</td><td align="left" colspan="1" rowspan="1">0.654</td><td align="left" colspan="1" rowspan="1">0.562</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;BUN</td><td align="left" colspan="1" rowspan="1">62.72</td><td align="left" colspan="1" rowspan="1">60.07&#8211;65.37</td><td align="left" colspan="1" rowspan="1">29.500</td><td align="left" colspan="1" rowspan="1">0.638</td><td align="left" colspan="1" rowspan="1">0.619</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ALB</td><td align="left" colspan="1" rowspan="1">51.35</td><td align="left" colspan="1" rowspan="1">48.56&#8211;54.15</td><td align="left" colspan="1" rowspan="1">3.450</td><td align="left" colspan="1" rowspan="1">0.844</td><td align="left" colspan="1" rowspan="1">0.237</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Crea</td><td align="left" colspan="1" rowspan="1">63.67</td><td align="left" colspan="1" rowspan="1">61.04&#8211;66.30</td><td align="left" colspan="1" rowspan="1">1.550</td><td align="left" colspan="1" rowspan="1">0.686</td><td align="left" colspan="1" rowspan="1">0.554</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;SOFA</td><td align="left" colspan="1" rowspan="1">55.38</td><td align="left" colspan="1" rowspan="1">52.65&#8211;58.10</td><td align="left" colspan="1" rowspan="1">6.500</td><td align="left" colspan="1" rowspan="1">0.793</td><td align="left" colspan="1" rowspan="1">0.308</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">LHR</italic> Lactate to hematocrit ratio, <italic toggle="yes">BUN</italic> Blood urea nitrogen, <italic toggle="yes">ALB</italic> Albumin, <italic toggle="yes">Crea</italic> Creatinine, <italic toggle="yes">SOFA</italic>&#160;Sequential Organ Failure Assessment</p></table-wrap-foot></table-wrap>
</p><p id="Par62">Although LHR outperformed the aforementioned indicators, it is noteworthy that its AUC values remained below 0.70 across all evaluated time points, indicating limited standalone predictive power from a clinical perspective. In light of this, we further assessed the incremental prognostic value of LHR when incorporated into a multivariate model adjusted for established risk factors, including demographics, comorbidities, and clinical interventions. The results, detailed in Supplementary Material, demonstrated that the inclusion of LHR significantly improved the model&#8217;s predictive performance, suggesting that LHR may serve as a valuable complementary marker within a comprehensive risk stratification framework.</p></sec><sec id="Sec15"><title>Subgroup analyses</title><p id="Par63">We further investigated the relationship between LHR and the risk of short- and long-term all-cause mortality after admission in different subpopulations. Stratified analyses based on age, sex, hypertension, respiratory failure, and coronary artery disease revealed no significant interactions between the LHR and most subgroups (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). These findings support the robustness of our conclusions.</p><p id="Par64">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Forest plots of stratified analyses of LHR (continuous) and 14-day <bold>A</bold>, 28-day <bold>B</bold>, and 90-day all-cause mortality in patients with cirrhosis and combined sepsis</p></caption><graphic id="d33e3299" position="float" orientation="portrait" xlink:href="12879_2025_11527_Fig6_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par65">Infection is closely associated with poor prognosis in patients with cirrhosis. The incidence of infections during hospitalization in patients with cirrhosis ranges from 25 to 35%, with even higher rates (up to 67%) observed in patients with decompensated cirrhosis [<xref ref-type="bibr" rid="CR5">5</xref>]. Although early antimicrobial therapy can be initiated in patients with cirrhosis, recurrent infections remain common due to compromised immune function and the prevalence of multidrug-resistant pathogens [<xref ref-type="bibr" rid="CR25">25</xref>]. Once the infections progress to sepsis, the risk of mortality in patients with cirrhosis increases significantly [<xref ref-type="bibr" rid="CR1">1</xref>]. Therefore, the early prediction of prognosis in patients with both cirrhosis and sepsis is of critical clinical importance for timely therapeutic intervention.</p><p id="Par66">This study retrospectively analyzed the clinical data of 1,881 patients with cirrhosis and sepsis from the MIMIC-IV (v 3.0) database. The results demonstrated significantly increased ICU; in-hospital; and 14-day, 28-day, and 90-day mortality rates after admission with increasing LHR values in patients with cirrhosis and sepsis. The Cox proportional hazards models confirmed a significant association between the LHR and 14-, 28-, and 90-day all-cause mortality. The RCS model revealed a nonlinear relationship between LHR and 14-, 28-, and 90-day all-cause mortality. The SOFA score is a widely recognized and reliable tool for assessing the prognosis of critically ill patients [<xref ref-type="bibr" rid="CR26">26</xref>]. However, our findings demonstrated that LHR outperformed the SOFA score in predicting both short- and long-term prognoses in patients with cirrhosis and sepsis. The subgroup analyses further supported the robustness of these results.</p><p id="Par67">To ensure methodological rigor, we first evaluated LHR as a continuous variable in both univariate and multivariate Cox regression models, confirming its independent association with short- and long-term all-cause mortality. Only after establishing this significant association did we proceed to identify an optimal cutoff value using maximally selected rank statistics. This stepwise strategy helped prevent reverse analytical reasoning and provided a statistically sound basis for subsequent stratified analyses, thereby enhancing the reliability and clinical applicability of our findings.</p><p id="Par68">LAC is a byproduct of anaerobic glucose glycolysis, particularly under hypoxic conditions [<xref ref-type="bibr" rid="CR27">27</xref>]. Patients with sepsis often show elevated LAC levels, reflecting pathological states such as systemic hypoxia, inadequate tissue perfusion, and abnormal cellular metabolism [<xref ref-type="bibr" rid="CR28">28</xref>]. Elevated LAC levels are markers of poor prognosis in patients [<xref ref-type="bibr" rid="CR28">28</xref>] with sepsis. Generally, increased LAC levels are closely associated with the severity of sepsis and organ dysfunction, such as renal failure and cardiopulmonary failure, with higher LAC levels correlating with an increased risk of mortality [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. HCT reflects the blood viscosity and oxygen transport capacity. In patients with cirrhosis, HCT levels may be lower owing to factors such as liver dysfunction, malnutrition, and anemia [<xref ref-type="bibr" rid="CR31">31</xref>]. Low HCT levels are also closely associated with anemia, reduced oxygen supply, metabolic abnormalities in cirrhosis, and hemodynamic changes induced by sepsis such as hypotension and hypovolemia [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par69">However, using LAC or HCT alone to evaluate the prognosis of patients with cirrhosis and septicemia may have some limitations. First, LAC levels are influenced by multiple factors, including tissue perfusion, hepatic metabolic capacity, and oxygen supply/demand balance, whereas HCT values are easily affected by interventions including fluid administration, bleeding, and dehydration. Therefore, the use of either of these markers alone lacks specificity. Second, cirrhosis with septicemia is a multisystem disorder involving liver function, renal function, circulatory status, and inflammatory response. Thus, LAC or HCT alone cannot comprehensively reflect a patient&#8217;s multi-organ functional status or disease complexity. Finally, elevated LAC levels in patients with cirrhosis may be related to impaired hepatic metabolic function; however, arterial LAC cannot directly distinguish liver-related LAC elevation from other causes, such as inadequate tissue perfusion.</p><p id="Par70">In recent years, LHR has garnered increasing attention [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] as a potential biomarker. LAC levels reflect tissue hypoxia or metabolic disturbances, whereas HCT levels reflect blood concentration or dilution, changes in blood volume, and degree of anemia. By combining these parameters into a ratio, the LHR provides a more comprehensive assessment of a patient&#8217;s circulatory system, tissue perfusion, and metabolic status, enabling a more precise evaluation of complex pathological processes. Higher LHR values may indicate severe hypoxia and a compromised hemodynamic status, which are associated with worse clinical outcomes.</p><p id="Par71">The LHR, as a composite indicator that integrates disturbances in oxygen metabolism and hemodilution status, may reflect more severe tissue hypoperfusion, microcirculatory dysfunction, and organ failure in patients with cirrhosis and sepsis. First, elevated lactate levels are a classical marker of tissue hypoxia and mitochondrial dysfunction [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>]. In the context of sepsis, hyperlactatemia is closely associated with circulatory failure and impaired cellular oxygen utilization. Prior studies have demonstrated that increased lactate levels not only result from systemic hypoperfusion but may also reflect impaired hepatic clearance, a condition particularly relevant in patients with underlying cirrhosis [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. Second, reduced HCT is commonly observed in cirrhotic patients and may be attributed to factors such as chronic blood loss, malnutrition, bone marrow suppression, and hypersplenism [<xref ref-type="bibr" rid="CR15">15</xref>]. A decline in HCT further compromises oxygen delivery to tissues, and when combined with elevated lactate, may indicate a worsening imbalance in oxygen supply and demand [<xref ref-type="bibr" rid="CR15">15</xref>]. Therefore, LHR, as a ratio of lactate to hematocrit, may serve as an integrative indicator of oxygenation failure and disease severity. In the setting of cirrhosis, it may sensitively reflect the transition from compensation to decompensation, thereby offering prognostic insight.</p><p id="Par72">Duan et al. [<xref ref-type="bibr" rid="CR31">31</xref>] demonstrated that LHR is an independent predictor of 30-day all-cause mortality in patients with sepsis and offers superior predictive performance compared with LAC or HCT alone. To the best of our knowledge, the present study is the first to highlight the prognostic value of the LHR in patients with cirrhosis and sepsis. Our findings confirmed significantly worse short- and long-term outcomes in patients with higher LHR values.</p><p id="Par73">By assessing LHR, clinicians may be able to more accurately predict patient outcomes and develop personalized treatment plans. For instance, in patients with elevated LHR, early interventions can be implemented, including optimizing oxygen therapy, improving hemodynamics, and addressing the sources of LAC production. These measures can help alleviate the patient&#8217;s metabolic burden and improve prognosis. Additionally, elevated LHR values are often associated with hemodynamic abnormalities, making fluid management a critical component of treatment. By evaluating the LHR, clinicians can tailor fluid administration or restriction based on the patient&#8217;s fluid status, avoiding both over-and undertreatment, thereby further optimizing therapeutic outcomes.</p><p id="Par74">This study has several strengths. First, this study is the first to evaluate the relationship between LHR and both short-term and long-term prognoses in critically ill patients with cirrhosis and sepsis. Second, robust real-world data from the MIMIC-IV (v 3.0) database allowed us to perform rigorous statistical adjustments to mitigate the influence of confounding factors on the results.</p><p id="Par75">However, this study has several limitations that should be acknowledged. First, the data were derived from the MIMIC-IV (v3.0) database, a single-center, ICU-based dataset collected from Beth Israel Deaconess Medical Center, a large tertiary academic hospital in the northeastern United States. As such, the study population may have greater disease severity and benefit from more advanced medical resources than patients in smaller or non-tertiary centers, potentially limiting the generalizability of our findings. Second, all enrolled patients were critically ill and admitted to the ICU, which inherently selects for a population with high baseline disease severity and mortality risk. Therefore, the prognostic value of the LHR demonstrated in this study may not be directly applicable to less severely ill patients, such as those managed in general wards or outpatient settings. Third, the demographic composition of the MIMIC-IV database is predominantly White and non-Hispanic, with limited ethnic and geographic diversity. This may further restrict the applicability of our findings to populations with different racial, ethnic, or regional characteristics. Multicenter validation in more diverse healthcare settings is warranted. Fourth, we extracted only the first recorded values of repeated-measure variables (e.g., vital signs, laboratory data) within 24&#160;h of ICU admission. While this approach reflects the patient&#8217;s initial physiological status and minimizes confounding from therapeutic interventions, it fails to capture the dynamic trends of lactate and hematocrit, which may provide additional prognostic information. Future studies incorporating longitudinal LHR trajectories may enhance predictive performance. Fifth, the etiology of cirrhosis was classified based on ICD-9/10 diagnostic codes, which, despite being a commonly accepted approach, may be subject to misclassification and limit etiological precision. Sixth, treatment-related variables such as mechanical ventilation, vasopressor use, and continuous renal replacement therapy were extracted only during the ICU stay. Interventions administered before ICU admission or after discharge were not considered, potentially omitting relevant therapeutic exposures and introducing bias related to treatment timing. Finally, for patients with multiple ICU admissions, only the first ICU stay was included in the analysis, which may introduce selection bias and limit the generalizability of the results across the full trajectory of critical illness.</p></sec><sec id="Sec17"><title>Conclusion</title><p id="Par76">Elevated LHR values are closely associated with a poor prognosis in critically ill patients with cirrhosis and sepsis. The LHR is a promising prognostic biomarker that may provide clinicians with a simple and effective tool for risk stratification and the early identification of patients at an increased risk of mortality.</p></sec><sec id="Sec18" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12879_2025_11527_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AUC</term><def><p id="Par5">Area under the curve</p></def></def-item><def-item><term>ANOVA</term><def><p id="Par6">Analysis of variance</p></def></def-item><def-item><term>BUN</term><def><p id="Par7">Blood urea nitrogen</p></def></def-item><def-item><term>CI</term><def><p id="Par8">Confidence interval</p></def></def-item><def-item><term>HCT</term><def><p id="Par9">Hematocrit</p></def></def-item><def-item><term>HR</term><def><p id="Par10">Hazard ratio</p></def></def-item><def-item><term>ICD-9</term><def><p id="Par11">International classification of diseases, 9th revision</p></def></def-item><def-item><term>ICD-10</term><def><p id="Par12">International classification of diseases,10th revision</p></def></def-item><def-item><term>ICU</term><def><p id="Par13">Intensive care unit</p></def></def-item><def-item><term>LAC</term><def><p id="Par14">Lactate</p></def></def-item><def-item><term>LHR</term><def><p id="Par15">Lactate-to-hematocrit ratio</p></def></def-item><def-item><term>MIMIC-IV</term><def><p id="Par16">Medical information mart for intensive care IV</p></def></def-item><def-item><term>RCS</term><def><p id="Par17">Restricted cubic spline</p></def></def-item><def-item><term>ROC</term><def><p id="Par18">Receiver operating characteristic</p></def></def-item><def-item><term>SOFA</term><def><p id="Par19">Sequential organ failure assessment</p></def></def-item><def-item><term>SQL</term><def><p id="Par20">Structured query language</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Jianjun Wang and Xi Chen contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are grateful to the MIMIV-IV (v 3.0) participants and staff. We appreciate all the reviewers who participated in the review.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>(I) Conception and design: JW, XC, SC, ZH, YL, RS; (II) Administrative support: JG, XZ, DW; (III) Provision of study material: JW, XC, SC, YL, RS, CQ; (IV) Collection and assembly of data: JW, XC, SC; (V) Data analysis and interpretation: JW, XC, SC, JG, XZ, DW; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. JW and XC contributed equally to this work and share first authorship. JG, XZ, and DW contributed equally to this work and share corresponding authorship.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by National Natural Science Foundation of China (NSFC) (Grant no.82400758), NHC Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital) (Grant no.2023HYX032), Health Commission of Sichuan Province Medical Science and Technology Program (Grant no.24QNMP028), Scientifc Research Project of Mianyang Health Commission (Grant no. 201926), Clinical Special Project of Mianyang Central Hospital (Grant no.2024LC007), and Medical Research Youth Innovation Project of Sichuan Province, China (Grant no.<ext-link ext-link-type="pmc:entrez-protein" xlink:href="Q23046">Q23046</ext-link>).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Raw data supporting the conclusions of this paper will be made available by the authors without reservation and can be requested from the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par77">This study was conducted using the MIMIC-IV (v3.0) database, a publicly available, de-identified dataset of critically ill patients. Access to the database and use of its data were approved by the Institutional Review Boards (IRBs) of the Massachusetts Institute of Technology (MIT) and Beth Israel Deaconess Medical Center (BIDMC), in accordance with the Health Insurance Portability and Accountability Act (HIPAA). The IRBs of MIT and BIDMC also waived the requirement for individual informed consent because all patient data in the MIMIC-IV database are fully anonymized before public release and the study was retrospective in nature. Researchers are granted access to the MIMIC-IV database only after completing the required Collaborative Institutional Training Initiative (CITI) program and obtaining certification in human subjects research. Our research team has completed the necessary training and obtained authorization to use the database for academic purposes. The research adhered to the ethical principles set forth in the Declaration of Helsinki, and all data usage complied with applicable regulations on privacy, data access, and ethical conduct, ensuring transparency, integrity, and ethical rigor throughout the study.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par78">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par79">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piano</surname><given-names>S</given-names></name><name name-style="western"><surname>Bunchorntavakul</surname><given-names>C</given-names></name><name name-style="western"><surname>Marciano</surname><given-names>S</given-names></name><etal/></person-group><article-title>Infections in cirrhosis</article-title><source>Lancet Gastroenterol Hepatol</source><year>2024</year><volume>9</volume><issue>8</issue><fpage>745</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(24)00078-5</pub-id><pub-id pub-id-type="pmid">38754453</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Piano S, Bunchorntavakul C, Marciano S, et al. Infections in cirrhosis. Lancet Gastroenterol Hepatol. 2024;9(8):745&#8211;57. 10.1016/S2468-1253(24)00078-5.<pub-id pub-id-type="pmid">38754453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(24)00078-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><collab>GBD 2017 Cirrhosis Collaborators</collab></person-group><article-title>The global, regional, and National burden of cirrhosis by cause in 195 countries and territories, 1990&#8211;2017: a systematic analysis for the global burden of disease study 2017</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><issue>3</issue><fpage>245</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(19)30349-8</pub-id><pub-id pub-id-type="pmid">31981519</pub-id><pub-id pub-id-type="pmcid">PMC7026710</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">GBD 2017 Cirrhosis Collaborators. The global, regional, and National burden of cirrhosis by cause in 195 countries and territories, 1990&#8211;2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245&#8211;66. 10.1016/S2468-1253(19)30349-8.<pub-id pub-id-type="pmid">31981519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(19)30349-8</pub-id><pub-id pub-id-type="pmcid">PMC7026710</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tapper</surname><given-names>EB</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>ND</given-names></name></person-group><article-title>Mortality due to cirrhosis and liver cancer in the united states, 1999&#8211;2016: observational study</article-title><source>BMJ</source><year>2018</year><volume>362</volume><fpage>k2817</fpage><pub-id pub-id-type="doi">10.1136/bmj.k2817</pub-id><pub-id pub-id-type="pmid">30021785</pub-id><pub-id pub-id-type="pmcid">PMC6050518</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the united states, 1999&#8211;2016: observational study. BMJ. 2018;362:k2817. 10.1136/bmj.k2817.<pub-id pub-id-type="pmid">30021785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k2817</pub-id><pub-id pub-id-type="pmcid">PMC6050518</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su&#225;rez</surname><given-names>M</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>R</given-names></name><name name-style="western"><surname>G&#243;mez-Molina</surname><given-names>R</given-names></name><etal/></person-group><article-title>Infection risk and management in patients with cirrhosis: A critical overview</article-title><source>World J Hepatol</source><year>2025</year><volume>17</volume><issue>5</issue><fpage>104468</fpage><pub-id pub-id-type="doi">10.4254/wjh.v17.i5.104468</pub-id><pub-id pub-id-type="pmid">40501475</pub-id><pub-id pub-id-type="pmcid">PMC12149902</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Su&#225;rez M, Mart&#237;nez R, G&#243;mez-Molina R, et al. Infection risk and management in patients with cirrhosis: A critical overview. World J Hepatol. 2025;17(5):104468. 10.4254/wjh.v17.i5.104468.<pub-id pub-id-type="pmid">40501475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4254/wjh.v17.i5.104468</pub-id><pub-id pub-id-type="pmcid">PMC12149902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piano</surname><given-names>S</given-names></name><name name-style="western"><surname>Tonon</surname><given-names>M</given-names></name><name name-style="western"><surname>Angeli</surname><given-names>P</given-names></name></person-group><article-title>Changes in the epidemiology and management of bacterial infections in cirrhosis</article-title><source>Clin Mol Hepatol</source><year>2021</year><volume>27</volume><issue>3</issue><fpage>437</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.3350/cmh.2020.0329</pub-id><pub-id pub-id-type="pmid">33504138</pub-id><pub-id pub-id-type="pmcid">PMC8273641</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol. 2021;27(3):437&#8211;45. 10.3350/cmh.2020.0329.<pub-id pub-id-type="pmid">33504138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3350/cmh.2020.0329</pub-id><pub-id pub-id-type="pmcid">PMC8273641</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>HF</given-names></name><name name-style="western"><surname>Kempe</surname><given-names>A</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>L</given-names></name></person-group><article-title>Venous vs arterial lactate and 30-Day mortality in pediatric Sepsis-Reply</article-title><source>JAMA Pediatr</source><year>2017</year><volume>171</volume><issue>8</issue><fpage>813</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2017.1601</pub-id><pub-id pub-id-type="pmid">28655033</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Scott HF, Kempe A, Bajaj L. Venous vs arterial lactate and 30-Day mortality in pediatric Sepsis-Reply. JAMA Pediatr. 2017;171(8):813&#8211;4. 10.1001/jamapediatrics.2017.1601.<pub-id pub-id-type="pmid">28655033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapediatrics.2017.1601</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><etal/></person-group><article-title>Serum lactate is an indicator for Short-Term and Long-Term mortality in patients with acute pancreatitis</article-title><source>Dig Dis Sci</source><year>2024</year><volume>69</volume><issue>6</issue><fpage>2223</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1007/s10620-024-08419-4</pub-id><pub-id pub-id-type="pmid">38594436</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Zeng Z, Huang R, Lin H, et al. Serum lactate is an indicator for Short-Term and Long-Term mortality in patients with acute pancreatitis. Dig Dis Sci. 2024;69(6):2223&#8211;34. 10.1007/s10620-024-08419-4.<pub-id pub-id-type="pmid">38594436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-024-08419-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Taotao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Evaluation of plasma lactate parameters for predicting mortality of septic patients</article-title><source>Heliyon</source><year>2022</year><volume>8</volume><issue>12</issue><fpage>e12340</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e12340</pub-id><pub-id pub-id-type="pmid">36582701</pub-id><pub-id pub-id-type="pmcid">PMC9792805</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wang M, Wang Y, Taotao L, et al. Evaluation of plasma lactate parameters for predicting mortality of septic patients. Heliyon. 2022;8(12):e12340. 10.1016/j.heliyon.2022.e12340.<pub-id pub-id-type="pmid">36582701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2022.e12340</pub-id><pub-id pub-id-type="pmcid">PMC9792805</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Association between lactate and 28-Day mortality in elderly patients with sepsis: results from MIMIC-IV database</article-title><source>Infect Dis Ther</source><year>2023</year><volume>12</volume><issue>2</issue><fpage>459</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s40121-022-00736-3</pub-id><pub-id pub-id-type="pmid">36520327</pub-id><pub-id pub-id-type="pmcid">PMC9925625</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">He L, Yang D, Ding Q, et al. Association between lactate and 28-Day mortality in elderly patients with sepsis: results from MIMIC-IV database. Infect Dis Ther. 2023;12(2):459&#8211;72. 10.1007/s40121-022-00736-3.<pub-id pub-id-type="pmid">36520327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40121-022-00736-3</pub-id><pub-id pub-id-type="pmcid">PMC9925625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Predictive value of arterial blood lactic acid concentration on the risk of in-Hospital All-Cause death in patients with acute heart failure</article-title><source>Int J Clin Pract</source><year>2022</year><volume>2022</volume><fpage>7644535</fpage><pub-id pub-id-type="doi">10.1155/2022/7644535</pub-id><pub-id pub-id-type="pmid">36474546</pub-id><pub-id pub-id-type="pmcid">PMC9683964</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hu W, Yuan L, Wang X, et al. Predictive value of arterial blood lactic acid concentration on the risk of in-Hospital All-Cause death in patients with acute heart failure. Int J Clin Pract. 2022;2022:7644535. 10.1155/2022/7644535.<pub-id pub-id-type="pmid">36474546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/7644535</pub-id><pub-id pub-id-type="pmcid">PMC9683964</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>T</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Outcomes of hyperlactatemia on admission in critically ill patients with acute myocardial infarction: A retrospective study from MIMIC-IV</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>1015298</fpage><pub-id pub-id-type="doi">10.3389/fendo.2022.1015298</pub-id><pub-id pub-id-type="pmid">36213274</pub-id><pub-id pub-id-type="pmcid">PMC9538672</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Lu T, Tan L, Xu K, et al. Outcomes of hyperlactatemia on admission in critically ill patients with acute myocardial infarction: A retrospective study from MIMIC-IV. Front Endocrinol (Lausanne). 2022;13:1015298. 10.3389/fendo.2022.1015298.<pub-id pub-id-type="pmid">36213274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.1015298</pub-id><pub-id pub-id-type="pmcid">PMC9538672</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katopodis</surname><given-names>P</given-names></name><name name-style="western"><surname>Pappas</surname><given-names>EM</given-names></name><name name-style="western"><surname>Katopodis</surname><given-names>KP</given-names></name></person-group><article-title>Acid-base abnormalities and liver dysfunction</article-title><source>Ann Hepatol</source><year>2022</year><volume>27</volume><issue>2</issue><fpage>100675</fpage><pub-id pub-id-type="doi">10.1016/j.aohep.2022.100675</pub-id><pub-id pub-id-type="pmid">35074477</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Katopodis P, Pappas EM, Katopodis KP. Acid-base abnormalities and liver dysfunction. Ann Hepatol. 2022;27(2):100675. 10.1016/j.aohep.2022.100675.<pub-id pub-id-type="pmid">35074477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.aohep.2022.100675</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jo</surname><given-names>IJ</given-names></name><etal/></person-group><article-title>Impact of Metformin use on lactate kinetics in patients with severe sepsis and septic shock</article-title><source>Shock</source><year>2017</year><volume>47</volume><issue>5</issue><fpage>582</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000000782</pub-id><pub-id pub-id-type="pmid">27792125</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Park J, Hwang SY, Jo IJ, et al. Impact of Metformin use on lactate kinetics in patients with severe sepsis and septic shock. Shock. 2017;47(5):582&#8211;7. 10.1097/SHK.0000000000000782.<pub-id pub-id-type="pmid">27792125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0000000000000782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fagerberg</surname><given-names>SK</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>LW</given-names></name><etal/></person-group><article-title>Erythrocyte P2&#8201;&#215;&#8201;1 receptor expression is correlated with change in haematocrit in patients admitted to the ICU with blood pathogen-positive sepsis</article-title><source>Crit Care</source><year>2018</year><volume>22</volume><issue>1</issue><fpage>181</fpage><pub-id pub-id-type="doi">10.1186/s13054-018-2100-3</pub-id><pub-id pub-id-type="pmid">30071869</pub-id><pub-id pub-id-type="pmcid">PMC6091015</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Fagerberg SK, Patel P, Andersen LW, et al. Erythrocyte P2X1 receptor expression is correlated with change in haematocrit in patients admitted to the ICU with blood pathogen-positive sepsis. Crit Care. 2018;22(1):181. 10.1186/s13054-018-2100-3.<pub-id pub-id-type="pmid">30071869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-018-2100-3</pub-id><pub-id pub-id-type="pmcid">PMC6091015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association between hematocrit and the 30-day mortality of patients with sepsis: A retrospective analysis based on the large-scale clinical database MIMIC-IV</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><issue>3</issue><fpage>e0265758</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0265758</pub-id><pub-id pub-id-type="pmid">35324947</pub-id><pub-id pub-id-type="pmcid">PMC8947025</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Luo M, Chen Y, Cheng Y, et al. Association between hematocrit and the 30-day mortality of patients with sepsis: A retrospective analysis based on the large-scale clinical database MIMIC-IV. PLoS ONE. 2022;17(3):e0265758. 10.1371/journal.pone.0265758.<pub-id pub-id-type="pmid">35324947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0265758</pub-id><pub-id pub-id-type="pmcid">PMC8947025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Min</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association between lactate/albumin ratio and prognosis in critically ill patients with acute kidney injury undergoing continuous renal replacement therapy</article-title><source>Ren Fail</source><year>2024</year><volume>46</volume><issue>2</issue><fpage>2374451</fpage><pub-id pub-id-type="doi">10.1080/0886022X.2024.2374451</pub-id><pub-id pub-id-type="pmid">38967166</pub-id><pub-id pub-id-type="pmcid">PMC11229749</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Liu J, Min J, Lu J, et al. Association between lactate/albumin ratio and prognosis in critically ill patients with acute kidney injury undergoing continuous renal replacement therapy. Ren Fail. 2024;46(2):2374451. 10.1080/0886022X.2024.2374451.<pub-id pub-id-type="pmid">38967166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/0886022X.2024.2374451</pub-id><pub-id pub-id-type="pmcid">PMC11229749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>The association between lactate dehydrogenase to serum albumin ratio and in-hospital mortality in patients with pulmonary embolism: a retrospective analysis of the MIMIC-IV database</article-title><source>Front Cardiovasc Med</source><year>2024</year><volume>11</volume><fpage>1398614</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2024.1398614</pub-id><pub-id pub-id-type="pmid">38962086</pub-id><pub-id pub-id-type="pmcid">PMC11220285</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Hu J, Zhou Y. The association between lactate dehydrogenase to serum albumin ratio and in-hospital mortality in patients with pulmonary embolism: a retrospective analysis of the MIMIC-IV database. Front Cardiovasc Med. 2024;11:1398614. 10.3389/fcvm.2024.1398614.<pub-id pub-id-type="pmid">38962086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2024.1398614</pub-id><pub-id pub-id-type="pmcid">PMC11220285</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Blood Urea nitrogen-to-albumin ratio independently predicts 30-day mortality in acute respiratory failure patients: a retrospective cohort study</article-title><source>J Thorac Dis</source><year>2024</year><volume>16</volume><issue>8</issue><fpage>4892</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.21037/jtd-24-298</pub-id><pub-id pub-id-type="pmid">39268142</pub-id><pub-id pub-id-type="pmcid">PMC11388210</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Xiao Q, Zhou Q, Shen W, et al. Blood Urea nitrogen-to-albumin ratio independently predicts 30-day mortality in acute respiratory failure patients: a retrospective cohort study. J Thorac Dis. 2024;16(8):4892&#8211;903. 10.21037/jtd-24-298.<pub-id pub-id-type="pmid">39268142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jtd-24-298</pub-id><pub-id pub-id-type="pmcid">PMC11388210</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Hong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prognostic impact of blood Urea nitrogen to albumin ratio on patients with sepsis: a retrospective cohort study</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>10013</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-37127-8</pub-id><pub-id pub-id-type="pmid">37340147</pub-id><pub-id pub-id-type="pmcid">PMC10282077</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Wang Y, Gao S, Hong L, et al. Prognostic impact of blood Urea nitrogen to albumin ratio on patients with sepsis: a retrospective cohort study. Sci Rep. 2023;13(1):10013. 10.1038/s41598-023-37127-8.<pub-id pub-id-type="pmid">37340147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-37127-8</pub-id><pub-id pub-id-type="pmcid">PMC10282077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Association between neutrophil-to-lymphocyte ratio and short-term all-cause mortality in patients with cerebrovascular disease admitted to the intensive care unit-a study based on the MIMIC-IV database</article-title><source>Front Med (Lausanne)</source><year>2024</year><volume>11</volume><fpage>1457364</fpage><pub-id pub-id-type="doi">10.3389/fmed.2024.1457364</pub-id><pub-id pub-id-type="pmid">39416871</pub-id><pub-id pub-id-type="pmcid">PMC11480710</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lin L, Yang J, Fu W, et al. Association between neutrophil-to-lymphocyte ratio and short-term all-cause mortality in patients with cerebrovascular disease admitted to the intensive care unit-a study based on the MIMIC-IV database. Front Med (Lausanne). 2024;11:1457364. 10.3389/fmed.2024.1457364.<pub-id pub-id-type="pmid">39416871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2024.1457364</pub-id><pub-id pub-id-type="pmcid">PMC11480710</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>An</surname><given-names>L</given-names></name><etal/></person-group><article-title>The neutrophil-to-lymphocyte ratio levels over time correlate to all-cause hospital mortality in sepsis</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><issue>16</issue><fpage>e36195</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e36195</pub-id><pub-id pub-id-type="pmid">39253154</pub-id><pub-id pub-id-type="pmcid">PMC11381600</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Zhang G, Wang T, An L, et al. The neutrophil-to-lymphocyte ratio levels over time correlate to all-cause hospital mortality in sepsis. Heliyon. 2024;10(16):e36195. 10.1016/j.heliyon.2024.e36195.<pub-id pub-id-type="pmid">39253154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e36195</pub-id><pub-id pub-id-type="pmcid">PMC11381600</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demir</surname><given-names>B</given-names></name><name name-style="western"><surname>&#350;a&#351;maz</surname><given-names>M&#304;</given-names></name><name name-style="western"><surname>Saglam Gurmen</surname><given-names>E</given-names></name><etal/></person-group><article-title>Prognostic value of lactate to hematocrit ratio score in patients with severe thoracoabdominal trauma</article-title><source>Ulus Travma Acil Cerrahi Derg</source><year>2022</year><volume>28</volume><issue>7</issue><fpage>927</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.14744/tjtes.2021.51189</pub-id><pub-id pub-id-type="pmid">35775673</pub-id><pub-id pub-id-type="pmcid">PMC10493832</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Demir B, &#350;a&#351;maz M&#304;, Saglam Gurmen E, et al. Prognostic value of lactate to hematocrit ratio score in patients with severe thoracoabdominal trauma. Ulus Travma Acil Cerrahi Derg. 2022;28(7):927&#8211;32. 10.14744/tjtes.2021.51189.<pub-id pub-id-type="pmid">35775673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14744/tjtes.2021.51189</pub-id><pub-id pub-id-type="pmcid">PMC10493832</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name><name name-style="western"><surname>Deutschman</surname><given-names>CS</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>CW</given-names></name><etal/></person-group><article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>8</issue><fpage>801</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmid">26903338</pub-id><pub-id pub-id-type="pmcid">PMC4968574</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801&#8211;10. 10.1001/jama.2016.0287.<pub-id pub-id-type="pmid">26903338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmcid">PMC4968574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Winsorization greatly reduces false positives by popular differential expression methods when analyzing human population samples</article-title><source>Genome Biol</source><year>2024</year><volume>25</volume><issue>1</issue><fpage>282</fpage><pub-id pub-id-type="doi">10.1186/s13059-024-03230-w</pub-id><pub-id pub-id-type="pmid">39478636</pub-id><pub-id pub-id-type="pmcid">PMC11523781</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Yang L, Zhang X, Chen J. Winsorization greatly reduces false positives by popular differential expression methods when analyzing human population samples. Genome Biol. 2024;25(1):282. 10.1186/s13059-024-03230-w.<pub-id pub-id-type="pmid">39478636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-024-03230-w</pub-id><pub-id pub-id-type="pmcid">PMC11523781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wong</surname><given-names>F</given-names></name><name name-style="western"><surname>Choudhury</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED consortium</article-title><source>Lancet Gastroenterol Hepatol</source><year>2024</year><volume>9</volume><issue>11</issue><fpage>997</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(24)00224-3</pub-id><pub-id pub-id-type="pmid">39243795</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Cao Z, Wong F, Choudhury AK, et al. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED consortium. Lancet Gastroenterol Hepatol. 2024;9(11):997&#8211;1009. 10.1016/S2468-1253(24)00224-3.<pub-id pub-id-type="pmid">39243795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(24)00224-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>de Mendon&#231;a</surname><given-names>A</given-names></name><name name-style="western"><surname>Cantraine</surname><given-names>F</given-names></name><etal/></person-group><article-title>Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on sepsis-related problems of the European society of intensive care medicine</article-title><source>Crit Care Med</source><year>1998</year><volume>26</volume><issue>11</issue><fpage>1793</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1097/00003246-199811000-00016</pub-id><pub-id pub-id-type="pmid">9824069</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Vincent JL, de Mendon&#231;a A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on sepsis-related problems of the European society of intensive care medicine. Crit Care Med. 1998;26(11):1793&#8211;800. 10.1097/00003246-199811000-00016.<pub-id pub-id-type="pmid">9824069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00003246-199811000-00016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedel</surname><given-names>WL</given-names></name><name name-style="western"><surname>Portela</surname><given-names>LV</given-names></name></person-group><article-title>Lactate levels in sepsis: don&#8217;t forget the mitochondria</article-title><source>Intensive Care Med</source><year>2024</year><volume>50</volume><issue>7</issue><fpage>1202</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1007/s00134-024-07475-8</pub-id><pub-id pub-id-type="pmid">38780796</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Nedel WL, Portela LV. Lactate levels in sepsis: don&#8217;t forget the mitochondria. Intensive Care Med. 2024;50(7):1202&#8211;3. 10.1007/s00134-024-07475-8.<pub-id pub-id-type="pmid">38780796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-024-07475-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Development and validation of a machine-learning model for predicting the risk of death in sepsis patients with acute kidney injury</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><issue>9</issue><fpage>e29985</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e29985</pub-id><pub-id pub-id-type="pmid">38699001</pub-id><pub-id pub-id-type="pmcid">PMC11064448</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Dong L, Liu P, Qi Z, et al. Development and validation of a machine-learning model for predicting the risk of death in sepsis patients with acute kidney injury. Heliyon. 2024;10(9):e29985. 10.1016/j.heliyon.2024.e29985.<pub-id pub-id-type="pmid">38699001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e29985</pub-id><pub-id pub-id-type="pmcid">PMC11064448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Souza</surname><given-names>DC</given-names></name><name name-style="western"><surname>Jabornisky</surname><given-names>R</given-names></name><name name-style="western"><surname>Kissoon</surname><given-names>N</given-names></name></person-group><article-title>Utility of lactate levels in the diagnosis and prognosis of septic shock</article-title><source>Pediatr Emerg Care</source><year>2024</year><volume>40</volume><issue>10</issue><fpage>736</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1097/PEC.0000000000003181</pub-id><pub-id pub-id-type="pmid">39514790</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">de Souza DC, Jabornisky R, Kissoon N. Utility of lactate levels in the diagnosis and prognosis of septic shock. Pediatr Emerg Care. 2024;40(10):736&#8211;45. 10.1097/PEC.0000000000003181.<pub-id pub-id-type="pmid">39514790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PEC.0000000000003181</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Lactate and lactylation in sepsis: A comprehensive review</article-title><source>J Inflamm Res</source><year>2024</year><volume>17</volume><fpage>4405</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.2147/JIR.S459185</pub-id><pub-id pub-id-type="pmid">39006496</pub-id><pub-id pub-id-type="pmcid">PMC11244620</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Liu S, Yang T, Jiang Q, et al. Lactate and lactylation in sepsis: A comprehensive review. J Inflamm Res. 2024;17:4405&#8211;17. 10.2147/JIR.S459185.<pub-id pub-id-type="pmid">39006496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S459185</pub-id><pub-id pub-id-type="pmcid">PMC11244620</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Ling</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association between lactate to hematocrit ratio and 30-day all-cause mortality in patients with sepsis: a retrospective analysis of the medical information Mart for intensive care IV database</article-title><source>Front Med (Lausanne)</source><year>2024</year><volume>11</volume><fpage>1422883</fpage><pub-id pub-id-type="doi">10.3389/fmed.2024.1422883</pub-id><pub-id pub-id-type="pmid">39193015</pub-id><pub-id pub-id-type="pmcid">PMC11347292</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Duan W, Yang F, Ling H, et al. Association between lactate to hematocrit ratio and 30-day all-cause mortality in patients with sepsis: a retrospective analysis of the medical information Mart for intensive care IV database. Front Med (Lausanne). 2024;11:1422883. 10.3389/fmed.2024.1422883.<pub-id pub-id-type="pmid">39193015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2024.1422883</pub-id><pub-id pub-id-type="pmcid">PMC11347292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turcato</surname><given-names>G</given-names></name><name name-style="western"><surname>Zaboli</surname><given-names>A</given-names></name><name name-style="western"><surname>Sibilio</surname><given-names>S</given-names></name><etal/></person-group><article-title>Estimated plasma volume status is a simple and quick tool that could help define the severity of patients with infection on arrival at the emergency department</article-title><source>Am J Med Sci</source><year>2024</year><volume>367</volume><issue>6</issue><fpage>343</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.amjms.2024.02.003</pub-id><pub-id pub-id-type="pmid">38354776</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Turcato G, Zaboli A, Sibilio S, et al. Estimated plasma volume status is a simple and quick tool that could help define the severity of patients with infection on arrival at the emergency department. Am J Med Sci. 2024;367(6):343&#8211;51. 10.1016/j.amjms.2024.02.003.<pub-id pub-id-type="pmid">38354776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjms.2024.02.003</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>